96 results on '"Theys, K"'
Search Results
2. Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir
- Author
-
Theys, K., Snoeck, J., Vercauteren, J., Abecasis, A. B., Vandamme, A.-M., and Camacho, R. J.
- Published
- 2013
- Full Text
- View/download PDF
3. HIV-1 Infection in Cyprus, the Eastern Mediterranean European Frontier: A Densely Sampled Transmission Dynamics Analysis from 1986 to 2012
- Author
-
Pineda-Peña, A.-C. Theys, K. Stylianou, D.C. Demetriades, I. Puchhammer, E. Vandamme, A.-M. Aleksiev, I. Lepej, S.Z. Linka, M. Fonager, J. Liitsola, K. Kaiser, R. Hamouda, O. Paraskevis, D. Coughlan, S. Grossman, Z. Mor, O. Zazzi, M. Griskevicius, A. Lipnickiene, V. Devaux, C. Boucher, C. Hofstra, M. Wensing, A. Bakken-Kran, A.-M. Horban, A. Camacho, R. Paraschiv, S. Otelea, D. Stanojevic, M. Stanekova, D. Poljak, M. Garcia, F. Paredes, R. Albert, J. Abecasis, A.B. Kostrikis, L.G.
- Subjects
virus diseases - Abstract
Since HIV-1 treatment is increasingly considered an effective preventionstrategy, it is important to study local HIV-1 epidemics to formulate tailored preventionpolicies. The prevalence of HIV-1 in Cyprus was historically low until 2005. To investigatethe shift in epidemiological trends, we studied the transmission dynamics of HIV-1 in Cyprususing a densely sampled Cypriot HIV-1 transmission cohort that included 85 percent ofHIV-1-infected individuals linked to clinical care between 1986 and 2012 based on detailedclinical, epidemiological, behavioral and HIV-1 genetic information. Subtyping andtransmission cluster reconstruction were performed using maximum likelihood and Bayesianmethods, and the transmission chain network was linked to the clinical, epidemiological andbehavioral data. The results reveal that for the main HIV-1 subtype A1 and B sub-epidemics,young and drug-naïve HIV-1-infected individuals in Cyprus are driving the dynamics of thelocal HIV-1 epidemic. The results of this study provide a better understanding of thedynamics of the HIV-1 infection in Cyprus, which may impact the development of preventionstrategies. Furthermore, this methodology for analyzing densely sampled transmissiondynamics is applicable to other geographic regions to implement effective HIV-1 preventionstrategies in local settings. © 2018 The Author(s).
- Published
- 2018
4. HIV-1 Infection in Cyprus, the Eastern Mediterranean European Frontier: A Densely Sampled Transmission Dynamics Analysis from 1986 to 2012
- Author
-
Pineda-Peña, A.-C. (Andrea-Clemencia), Theys, K. (Kristof), Stylianou, D.C. (Dora C.), Demetriades, I. (I.), Puchhammer, E. (Elisabeth), Vandamme, A.M. (Anne Mieke), Aleksiev, I. (Ivailo), Lepej, S.Z. (Snjezana), Linka, M. (Marek), Fonager, J. (Jannik), Liitsola, K. (Kirsi), Kaiser, R. (Rolf), Hamouda, O. (Osamah), Paraskevis, D. (Dimitrios), Coughlan, S. (Suzie), Grossman, Z. (Zehava), Mor, O. (Orna), Zazzi, M. (Maurizio), Griskevicius, A. (Algirdas), Lipnickiene, V., Devaux, C. (Carole), Boucher, C. (Charles), Hofstra, M. (Marije), Wensing, A. (Amj), Bakken-Kran, A.-M. (Anne-Marte), Horban, A. (Andrzej), Camacho, R.J. (Ricardo Jorge), Paraschiv, C. (Corina), Otelea, D. (Dan), Stanojevic, M. (Maja), Stanekova, D. (Danica), Poljak, M. (Mario), Garcia, F. (Federico), Paredes, R. (Roger), Albert, J. (Jan), Abecasis, A.B. (Ana), Kostrikis, L.G. (Leondios), Pineda-Peña, A.-C. (Andrea-Clemencia), Theys, K. (Kristof), Stylianou, D.C. (Dora C.), Demetriades, I. (I.), Puchhammer, E. (Elisabeth), Vandamme, A.M. (Anne Mieke), Aleksiev, I. (Ivailo), Lepej, S.Z. (Snjezana), Linka, M. (Marek), Fonager, J. (Jannik), Liitsola, K. (Kirsi), Kaiser, R. (Rolf), Hamouda, O. (Osamah), Paraskevis, D. (Dimitrios), Coughlan, S. (Suzie), Grossman, Z. (Zehava), Mor, O. (Orna), Zazzi, M. (Maurizio), Griskevicius, A. (Algirdas), Lipnickiene, V., Devaux, C. (Carole), Boucher, C. (Charles), Hofstra, M. (Marije), Wensing, A. (Amj), Bakken-Kran, A.-M. (Anne-Marte), Horban, A. (Andrzej), Camacho, R.J. (Ricardo Jorge), Paraschiv, C. (Corina), Otelea, D. (Dan), Stanojevic, M. (Maja), Stanekova, D. (Danica), Poljak, M. (Mario), Garcia, F. (Federico), Paredes, R. (Roger), Albert, J. (Jan), Abecasis, A.B. (Ana), and Kostrikis, L.G. (Leondios)
- Abstract
Since HIV-1 treatment is increasingly considered an effective preventionstrategy, it is important to study local HIV-1 epidemics to formulate tailored preventionpolicies. The prevalence of HIV-1 in Cyprus was historically low until 2005. To investigatethe shift in epidemiological trends, we studied the transmission dynamics of HIV-1 in Cyprususing a densely sampled Cypriot HIV-1 transmission cohort that included 85 percent ofHIV-1-infected individuals linked to clinical care between 1986 and 2012 based on detailedclinical, epidemiological, behavioral and HIV-1 genetic information. Subtyping andtransmission cluster reconstruction were performed using maximum likelihood and Bayesianmethods, and the transmission chain network was linked to the clinical, epidemiological andbehavioral data. The results reveal that for the main HIV-1 subtype A1 and B sub-epidemics,young and drug-naïve HIV-1-infected individuals in Cyprus are driving the dynamics of thelocal HIV-1 epidemic. The results of this study provide a better understanding of thedynamics of the HIV-1 infection in Cyprus, which may impact the development of preventionstrategies. Furthermore, this methodology for analyzing densely sampled transmissiondynamics is applicable to other geographic regions to implement effective HIV-1 preventionstrategies in local settings.
- Published
- 2018
- Full Text
- View/download PDF
5. HIV-1 Infection in Cyprus, the Eastern Mediterranean European Frontier: A Densely Sampled Transmission Dynamics Analysis from 1986 to 2012
- Author
-
Pineda-Peña, AC, Theys, K, Stylianou, D C, Demetriades, I, Puchhammer, E, Vandamme, AM, Aleksiev, I, Lepej, SZ, Linka, M, Fonager, J, Liitsola, K, Kaiser, R, Hamouda, O, Paraskevis, D, Coughlan, S, Grossman, Z, Mor, O, Zazzi, M, Griskevicius, A, Lipnickiene, V, Devaux, C, Boucher, Charles, Hofstra, M, Wensing, A, Bakken-Kran, AM, Horban, A, Camacho, R, Paraschiv, S, Otelea, D, Stanojevic, M, Stanekova, D, Poljak, M, Garcia, F, Paredes, R, Albert, J, Abecasis, AB, Kostrikis, LG, Pineda-Peña, AC, Theys, K, Stylianou, D C, Demetriades, I, Puchhammer, E, Vandamme, AM, Aleksiev, I, Lepej, SZ, Linka, M, Fonager, J, Liitsola, K, Kaiser, R, Hamouda, O, Paraskevis, D, Coughlan, S, Grossman, Z, Mor, O, Zazzi, M, Griskevicius, A, Lipnickiene, V, Devaux, C, Boucher, Charles, Hofstra, M, Wensing, A, Bakken-Kran, AM, Horban, A, Camacho, R, Paraschiv, S, Otelea, D, Stanojevic, M, Stanekova, D, Poljak, M, Garcia, F, Paredes, R, Albert, J, Abecasis, AB, and Kostrikis, LG
- Published
- 2018
6. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study
- Author
-
Gregson, J, Tang, M, Ndembi, N, Hamers, Rl, Marconi, Vc, Brooks, K, Theys, K, Arruda, M, Garcia, F, Monge, S, Kanki, Pj, Kumarasamy, N, Kerschberger, B, Mor, O, Charpentier, C, Todesco, E, Rokx, C, Gras, L, Halvas, Ek, Sunpath, H, Carlo, Dd, Antinori, A, Andreoni, M, Latini, A, Mussini, C, Aghokeng, A, Sonnerborg, A, Neogi, U, Fessel, Wj, Agolory, S, Yang, C, Blanco, Jl, Juma, Jm, Smit, E, Schmidt, D, Watera, C, Asio, J, Kirungi, W, Tostevin, A, Clumeck, N, Goedhals, D, Bester, Pa, Sabin, C, Mukui, I, Santoro, M, Perno, Cf, Hunt, G, Morris, L, Pillay, D, Schulter, E, Reyes-Teran, G, Romero, K, Avila-Rios, S, Sirivichayakul, S, Ruxrungtham, K, Mekprasan, S, Dunn, D, Kaleebu, P, Raizes, E, Kantor, R, Gupta, Rk, Rhee, S, Shafer, Rw, de Wit, Tfr, Diero, L, Camacho, R, Gunthard, Hf, Hoffmann, Cj, Di Carlo, D, El-Hay, T, van Vuuren, C, de Oliveira, T, Murakami-Ogasawara, A, [Pillay, Deenan] UCL, Dept Infect, London WC1E 6BT, England, [Gupta, Ravindra K.] UCL, Dept Infect, London WC1E 6BT, England, [Tang, Michele] Stanford Univ, Dept Med, Stanford, CA 94305 USA, [Rhee, Soo-Yon] Stanford Univ, Dept Med, Stanford, CA 94305 USA, [Shafer, Robert W.] Stanford Univ, Dept Med, Stanford, CA 94305 USA, [Gregson, John] London Sch Hyg & Trop Med, Dept Stat, London, England, [Ndembi, Nicaise] Inst Human Virol Nigeria, Abuja, Federal Capital, Nigeria, [Hamers, Raph L.] Univ Amsterdam, Acad Med Ctr, Amsterdam Inst Global Hlth & Dev, Dept Global Hlth, NL-1012 WX Amsterdam, Netherlands, [de Wit, Tobias F. Rinke] Univ Amsterdam, Acad Med Ctr, Amsterdam Inst Global Hlth & Dev, Dept Global Hlth, NL-1012 WX Amsterdam, Netherlands, [Hamers, Raph L.] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1012 WX Amsterdam, Netherlands, [de Wit, Tobias F. Rinke] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1012 WX Amsterdam, Netherlands, [Marconi, Vincent C.] Emory Univ, Rollins Sch Publ Hlth, Dept Global Hlth, Atlanta, GA 30322 USA, [Marconi, Vincent C.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA, [Diero, Lameck] Moi Univ, Eldoret, Kenya, [Diero, Lameck] Acad Model Providing Access Healthcare, Eldoret, Kenya, [Brooks, Katherine] Brown Univ, Alpert Med Sch, Div Infect Dis, Providence, RI 02912 USA, [Theys, Kristof] KU Leuven Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, B-3000 Leuven, Belgium, [Camacho, Ricardo] KU Leuven Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, B-3000 Leuven, Belgium, [Kantor, Rami] KU Leuven Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, B-3000 Leuven, Belgium, [Arruda, Monica] Univ Fed Rio de Janeiro, Inst Biol, LVM, BR-21941 Rio De Janeiro, Brazil, [Garcia, Frederico] Complejo Hosp Univ Granada, Granada, Spain, Univ Alcala de Henares, E-28871 Alcala De Henares, Spain, [Monge, Susana] CIBERESP, Madrid, Spain, [Gunthard, Huldrych F.] Univ Zurich, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland, [Gunthard, Huldrych F.] Univ Zurich, Inst Med Virol, Zurich, Switzerland, [Hoffmann, Christopher J.] Johns Hopkins Univ, Baltimore, MD USA, [Hoffmann, Christopher J.] Aurum Inst, Johannesburg, South Africa, [Kanki, Phyllis J.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA, [Kumarasamy, Nagalingeshwaran] VHS, YRGCARE Med Ctr, Chennai, Tamil Nadu, India, [Kerschberger, Bernard] Med Sans Frontieres Operat Ctr Geneva, Mbabane, Eswatini, [Mor, Orna] Israel Minist Hlth, Publ Hlth Serv, Cent Virol Lab, Jerusalem, Israel, [Charpentier, Charlotte] Univ Paris Diderot, Sorbonne Paris Cite, IAME, UMR 1137, Paris, France, [Charpentier, Charlotte] INSERM, IAME, UMR 1137, Paris, France, [Charpentier, Charlotte] Hop Bichat Claude Bernard, AP HP, Virol Lab, F-75018 Paris, France, [Todesco, Eva] Hop La Pitie Salpetriere, Lab Virol, Paris, France, [Rokx, Casper] Erasmus Univ, Med Ctr, Dept Internal Med Infect Dis, Rotterdam, Netherlands, [Gras, Luuk] Stichting HIV Monitoring, Amsterdam, Netherlands, [Halvas, Elias K.] Univ Pittsburgh, Pittsburgh, PA USA, [Sunpath, Henry] Ethekwini Dist Hlth Off, Kwa Zulu, South Africa, [Di Carlo, Domenico] Univ Roma Tor Vergata, Dept Expt Med & Surg, Rome, Italy, [Santoro, Maria M.] Univ Roma Tor Vergata, Dept Expt Med & Surg, Rome, Italy, [Antinori, Antonio] INMI L Spallanzani, Infect Dis Unit, Rome, Italy, [Andreoni, Massimo] Univ Hosp Tor Vergata, Clin Infect Dis, Rome, Italy, [Latini, Alessandra] San Gallicano Dermatol Inst, HIV AIDS Unit, Rome, Italy, [Mussini, Cristina] Azienda Osped Univ Policlin, Clin Infect Dis, Modena, Italy, [Aghokeng, Avelin] Virol Lab CREMER IMPM, Yaounde, Cameroon, [Sonnerborg, Anders] Karolinska Inst, Div Clin Microbiol, Stockholm, Sweden, [Neogi, Ujjwal] Karolinska Inst, Div Clin Microbiol, Stockholm, Sweden, [Sonnerborg, Anders] Karolinska Inst, Infect Dis Unit, Stockholm, Sweden, [Neogi, Ujjwal] Karolinska Inst, Infect Dis Unit, Stockholm, Sweden, [Sonnerborg, Anders] Karolinska Univ Hosp, Stockholm, Sweden, [Neogi, Ujjwal] Karolinska Univ Hosp, Stockholm, Sweden, [Fessel, William J.] Kaiser Permanente Med Care Program Northern Calif, San Francisco, CA USA, [Agolory, Simon] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA, [Raizes, Elliot] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA, [Yang, Chunfu] Ctr Dis Control & Prevent, Int Lab Branch, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA, [Blanco, Jose L.] Univ Barcelona, Inst Invest Biomed August Pi i Sunyer, Clin Univ, Barcelona, Spain, [Juma, James M.] Minist Hlth & Social Welf, Dar Es Salaam, Tanzania, [Smit, Erasmus] Publ Hlth England, Publ Hlth Lab, Birmingham, W Midlands, England, [Schmidt, Daniel] Robert Koch Inst, Dept Infect Dis Epidemiol HIV AIDS STI & Blood Bo, Berlin, Germany, [Watera, Christine] Uganda Res Unit AIDS, Entebbe, Uganda, [Asio, Juliet] Uganda Res Unit AIDS, Entebbe, Uganda, [Kaleebu, Pontiano] Uganda Res Unit AIDS, Entebbe, Uganda, [Tostevin, Anna] Minist Hlth, Kampala, Uganda, [Tostevin, Anna] UCL, MRC Clin Trials Unit, London, England, [Dunn, David] UCL, MRC Clin Trials Unit, London, England, [El-Hay, Tal] IBM Haifa Res Lab, Haifa, Israel, [Clumeck, Nathan] Univ Libre Bruxelles, St Pierre Univ Hosp, Brussels, Belgium, [Goedhals, Dominique] Univ Orange Free State, Dept Med Microbiol & Virol, Natl Hlth Lab Serv, Bloemfontein, South Africa, [van Vuuren, Cloete] Univ Orange Free State, Dept Med Microbiol & Virol, Natl Hlth Lab Serv, Bloemfontein, South Africa, [Sabin, Caroline] UCL, Infect & Populat Hlth, London, England, [Mukui, Irene] Minist Hlth, Natl AIDS & STI Control Programme, Nairobi, Kenya, [Perno, Carlo F.] INMI L Spallanzani, Antiretroviral Drugs Monitoring Unit, Rome, Italy, [Hunt, Gillian] Natl Inst Communicable Dis, Johannesburg, South Africa, [Morris, Lynn] Natl Inst Communicable Dis, Johannesburg, South Africa, [de Oliveira, Tulio] Wellcome Trust Africa Ctr Hlth & Populat Studies, Durban, South Africa, [Pillay, Deenan] Wellcome Trust Africa Ctr Hlth & Populat Studies, Durban, South Africa, [de Oliveira, Tulio] Univ KwaZulu Natal, Coll Hlth Sci, Durban, South Africa, [Schulter, Eugene] Univ Cologne, Inst Virol, D-50931 Cologne, Germany, [Murakami-Ogasawara, Akio] Natl Inst Resp Dis, Ctr Res Infect Dis, Mexico City, DF, Mexico, [Sirivichayakul, Sunee] Chulalongkorn Univ, Dept Med, Bangkok, Thailand, [Ruxrungtham, Kiat] Chulalongkorn Univ, Dept Med, Bangkok, Thailand, [Mekprasan, Suwanna] Chulalongkorn Univ, Dept Med, Bangkok, Thailand, [Kaleebu, Pontiano] MRC UVRI Uganda Res Unit AIDS, Entebbe, Uganda, Wellcome Trust, MRC, NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, and Medical Research Council
- Subjects
Cyclopropanes ,Anti-HIV Agents ,K65r ,Drug Resistance ,Antiretroviral Therapy ,HIV Infections ,Global Health ,Settore MED/07 ,Virological failure ,Tenofovir disoproxil fumarate ,Antiretroviral Therapy, Highly Active ,Drug Resistance, Viral ,Humans ,Emtricitabine ,Transmission ,Highly Active ,Viral ,Tenofovir ,Africa South of the Sahara ,Benzoxazines ,HIV-1 ,Lamivudine ,Pre-Exposure Prophylaxis ,Retrospective Studies ,Reverse Transcriptase Inhibitors ,Viral Load ,Hiv-1-infected patients ,virus diseases ,Articles ,Antiretroviral therapy ,Naive patients ,Alkynes ,Efavirenz - Abstract
Summary Background Antiretroviral therapy (ART) is crucial for controlling HIV-1 infection through wide-scale treatment as prevention and pre-exposure prophylaxis (PrEP). Potent tenofovir disoproxil fumarate-containing regimens are increasingly used to treat and prevent HIV, although few data exist for frequency and risk factors of acquired drug resistance in regions hardest hit by the HIV pandemic. We aimed to do a global assessment of drug resistance after virological failure with first-line tenofovir-containing ART. Methods The TenoRes collaboration comprises adult HIV treatment cohorts and clinical trials of HIV drug resistance testing in Europe, Latin and North America, sub-Saharan Africa, and Asia. We extracted and harmonised data for patients undergoing genotypic resistance testing after virological failure with a first-line regimen containing tenofovir plus a cytosine analogue (lamivudine or emtricitabine) plus a non-nucleotide reverse-transcriptase inhibitor (NNRTI; efavirenz or nevirapine). We used an individual participant-level meta-analysis and multiple logistic regression to identify covariates associated with drug resistance. Our primary outcome was tenofovir resistance, defined as presence of K65R/N or K70E/G/Q mutations in the reverse transcriptase (RT) gene. Findings We included 1926 patients from 36 countries with treatment failure between 1998 and 2015. Prevalence of tenofovir resistance was highest in sub-Saharan Africa (370/654 [57%]). Pre-ART CD4 cell count was the covariate most strongly associated with the development of tenofovir resistance (odds ratio [OR] 1·50, 95% CI 1·27–1·77 for CD4 cell count
- Published
- 2016
7. BEST HOPE - Cohort of HIV newly diagnosed patients in Portugal
- Author
-
Pingarilho, M., Pineda-Peña, A.C., Dias, S., Pimentel, V.F., Libin, P., Aleixo, M.J., Amaral-Alves, D., Ascenção, B., Azevedo, F., Baptista, T., Bredes, C., Brito, P., Cabanas, J., Cabo, J., Caixeiro, M., Caldas, C., Campos, Maria José, Cardoso, S., Carvalho, A.P., Casella, I., Correia, L., Correia-Abreu, R., Côrte-Real, R., Costa, I., Costa, O., Cunha, S., Diogo, I., Faria, D., Faria, T., Feijó, M., Ferreira, J., Germano, I., Gomes, A., Gomes, P., Gonçalves, F., Gonçalves, M.J., Granado, A., Ivo, M.S., Jesus, J., Koch, C., Lino, S., Luís, N., Maio, A., Maltez, F., Mansinho, K., Marques, N., Marques, S., Martins, S., Mateus, E., Mendão, Luís, Messias, C., Monteiro, F., Morais, C., Mota, V., Neves, I., Nunes, S., Oliveira, J., Pacheco, P., Pereira, H., Pereira-Vaz, J., Pessanha, M., Pimenta, A., Piñeiro, C., Pinheiro, S., Pinho, R., Poças, J., Proença, P., Ramos, H., Rocha, Miguel, Rodrigues, C., Rodrigues, P., Rodrigues, R., Roxo, F., Sá, J., Salvado, C., Sarmento-Castro, R., Seixas, D., Serrão, R., Silva, A.R., Silva, E.G., Silva, V., Simão, M., Simões, D., Simões, J., Simões, P., Soares, J., Tavares, R., Teófilo, E., Trigo, D., Theys, K., Martins M.R.O., Vandamme, A.M., Camacho, R.J., and Abecasis AB
- Published
- 2016
- Full Text
- View/download PDF
8. RegaDB: Community-driven data management and analysis for infectious diseases
- Author
-
Libin, P, Beheydt, G, Deforche, K, Imbrechts, S, Ferreira, F, Van Laethem, K, Theys, K, Carvalho, A, Cavaco-Silva, J, Lapadula, G, Torti, C, Assel, M, Wesner, S, Snoeck, J, Ruelle, J, De Bel, A, Lacor, P, De Munter, P, Van Wijngaerden, E, Zazzi, M, Kaiser, R, Ayouba, A, Peeters, M, De Oliveira, T, Alcantara, L, Grossman, Z, Sloot, P, Otelea, D, Paraschiv, S, Boucher, C, Camacho, R, Vandamme, A, Libin P., Beheydt G., Deforche K., Imbrechts S., Ferreira F., Van Laethem K., Theys K., Carvalho A. P., Cavaco-Silva J., Lapadula G., Torti C., Assel M., Wesner S., Snoeck J., Ruelle J., De Bel A., Lacor P., De Munter P., Van Wijngaerden E., Zazzi M., Kaiser R., Ayouba A., Peeters M., De Oliveira T., Alcantara L. C. J., Grossman Z., Sloot P., Otelea D., Paraschiv S., Boucher C., Camacho R. J., Vandamme A. -M., Libin, P, Beheydt, G, Deforche, K, Imbrechts, S, Ferreira, F, Van Laethem, K, Theys, K, Carvalho, A, Cavaco-Silva, J, Lapadula, G, Torti, C, Assel, M, Wesner, S, Snoeck, J, Ruelle, J, De Bel, A, Lacor, P, De Munter, P, Van Wijngaerden, E, Zazzi, M, Kaiser, R, Ayouba, A, Peeters, M, De Oliveira, T, Alcantara, L, Grossman, Z, Sloot, P, Otelea, D, Paraschiv, S, Boucher, C, Camacho, R, Vandamme, A, Libin P., Beheydt G., Deforche K., Imbrechts S., Ferreira F., Van Laethem K., Theys K., Carvalho A. P., Cavaco-Silva J., Lapadula G., Torti C., Assel M., Wesner S., Snoeck J., Ruelle J., De Bel A., Lacor P., De Munter P., Van Wijngaerden E., Zazzi M., Kaiser R., Ayouba A., Peeters M., De Oliveira T., Alcantara L. C. J., Grossman Z., Sloot P., Otelea D., Paraschiv S., Boucher C., Camacho R. J., and Vandamme A. -M.
- Abstract
RegaDB is a free and open source data management and analysis environment for infectious diseases. RegaDB allows clinicians to store, manage and analyse patient data, including viral genetic sequences. Moreover, RegaDB provides researchers with a mechanism to collect data in a uniform format and offers them a canvas to make newly developed bioinformatics tools available to clinicians and virologists through a user friendly interface. © 2013 The Author. Published by Oxford University Press.
- Published
- 2013
9. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study
- Author
-
Gregson, J, Tang, M, Ndembi, N, Hamers, R, Marconi, V, Brooks, K, Theys, K, Arruda, M, Garcia, F, Monge, S, Kanki, P, Kumarasamy, N, Kerschberger, B, Mor, O, Charpentier, C, Todesco, E, Rokx, C, Gras, L, Halvas, E, Sunpath, H, Carlo, D, Antinori, A, Andreoni, M, Latini, A, Mussini, C, Aghokeng, A, Sonnerborg, A, Neogi, U, Fessel, W, Agolory, S, Yang, C, Blanco, J, Juma, J, Smit, E, Schmidt, D, Watera, C, Asio, J, Kirungi, W, Tostevin, A, Clumeck, N, Goedhals, D, Bester, P, Sabin, C, Mukui, I, Santoro, M, Perno, C, Hunt, G, Morris, L, Camacho, R, Pillay, D, Schulter, E, Reyes-Terán, G, Romero, K, Avila-Rios, S, Sirivichayakul, S, Ruxrungtham, K, Mekprasan, S, Dunn, D, Kaleebu, P, Raizes, E, Kantor, R, Shafer, R, Gupta, R, Rhee, S, De Wit, T, Diero, L, Günthard, H, Hoffmann, C, and Di Carlo, D
- Subjects
virus diseases - Abstract
Background Antiretroviral therapy (ART) is crucial for controlling HIV-1 infection through wide-scale treatment as prevention and pre-exposure prophylaxis (PrEP). Potent tenofovir disoproxil fumarate-containing regimens are increasingly used to treat and prevent HIV, although few data exist for frequency and risk factors of acquired drug resistance in regions hardest hit by the HIV pandemic. We aimed to do a global assessment of drug resistance after virological failure with first-line tenofovir-containing ART. Methods The TenoRes collaboration comprises adult HIV treatment cohorts and clinical trials of HIV drug resistance testing in Europe, Latin and North America, sub-Saharan Africa, and Asia. We extracted and harmonised data for patients undergoing genotypic resistance testing after virological failure with a first-line regimen containing tenofovir plus a cytosine analogue (lamivudine or emtricitabine) plus a non-nucleotide reverse-transcriptase inhibitor (NNRTI; efavirenz or nevirapine). We used an individual participant-level meta-analysis and multiple logistic regression to identify covariates associated with drug resistance. Our primary outcome was tenofovir resistance, defined as presence of K65R/N or K70E/G/Q mutations in the reverse transcriptase (RT) gene. Findings We included 1926 patients from 36 countries with treatment failure between 1998 and 2015. Prevalence of tenofovir resistance was highest in sub-Saharan Africa (370/654 [57%]). Pre-ART CD4 cell count was the covariate most strongly associated with the development of tenofovir resistance (odds ratio [OR] 1·50, 95% CI 1·27–1·77 for CD4 cell count
- Published
- 2015
10. Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients
- Author
-
Moutschen, M., Theys, K., Deforche, K., Vercauteren, J., Libin, P., van de Vijver, D. A. M. C., Albert, Jan, Åsjö, Birgitta, Balotta, Claudia, Bruckova, M., Camacho, Ricardo J., Clotet, B., Coughlan, S., Grossman, Z., Hamouda, O., Horban, A., Korn, K., Kostrikis, Leontios G., Kücherer, C., Nielsen, C., Paraskevis, Dimitrios N., Poljak, M., Puchhammer-Stockl, E., Riva, C., Ruiz, L., Liitsola, K., Schmit, J. -C, Schuurman, R., Sönnerborg, A., Stanekova, D., Stanojevic, M., Struck, D., Van Laethem, K., Wensing, A. M. J., Boucher, C. A. B., Vandamme, A. M., Sarcletti, M., Schmied, B., Geit, M., Balluch, G., Derdelinckx, I., Sasse, A., Bogaert, M., Ceunen, H., De Roo, A., De Wit, S., Echahidi, F., Fransen, K., Goffard, J. -C, Goubau, P., Goudeseune, E., Yombi, J. -C, Lacor, P., Liesnard, C., Pierard, D., Rens, R., Schrooten, Y., Vaira, D., Van den Heuvel, A., Van Der Gucht, B., Van Ranst, M., Van Wijngaerden, E., Vandercam, B., Vekemans, M., Verhofstede, C., Clumeck, N., Demetriades, Ioannis, Kousiappa, Ioanna, Demetriou, Victoria L., Hezka, Johana, Linka, M., Machala, L., Jrgensen, L. B., Gerstoft, J., Mathiesen, L., Pedersen, C., Nielsen, H., Laursen, A., Kvinesdal, B., Ristola, M., Suni, J., Sutinen, J., K̈ucherer, C., Berg, T., Braun, P., Poggensee, G., Däumer, M., Eberle, J., Heiken, H., Kaiser, R., Knechten, H., Müller, H., Neifer, S., Schmidt, B., Walter, H., Gunsenheimer-Bartmeyer, B., Harrer, T., Hatzakis, Angelos E., Magiorkinis, Emmanouil N., Hatzitheodorou, Eleni, Issaris, C., Haida, Catherine, Zavitsanou, Assimina, Magiorkinis, Gkikas, Lazanas, Marios C., Chini, Maria C., Magafas, N., Tsogas, Nickolaos, Paparizos, Vassilios A., Kourkounti, Sofia, Antoniadou, Anastasia C., Papadopoulos, Antonios I., Panagopoulos, Periklis, Poulakou, Garyphallia G., Sakka, V., Chryssos, Georgios, Drimis, Stylianos, Gargalianos, Panagiotis, Lelekis, Moyssis I., Xilomenos, G., Psichogiou, Mina A., Daikos, George L., Panos, George, Haratsis, G., Kordossis, Theodore, Kontos, Athanasios N., Koratzanis, Georgios, Theodoridou, Maria C., Mostrou, Glykeria J., Spoulou, Vana I., Hall, W., De Gascun, C., Byrne, C., Duffy, M., Bergin, C., Reidy, D., Farrell, G., Lambert, J., O'Connor, E., Rochford, A., Low, J., Coakely, P., Levi, I., Chemtob, D., Mussini, C., Caramma, I., Capetti, A., Colombo, M. C., Rossi, C., Prati, F., Tramuto, F., Vitale, F., Ciccozzi, M., Angarano, G., Rezza, G., Schmit, J. C., Hemmer, R., Arendt, V., Staub, T., Schneider, F., Roman, F., van Bentum, P. H. M., Brinkman, K., op de Coul, E. L., van der Ende, M. E., Hoepelman, I. M., van Kasteren, M., Juttmann, J., Kuipers, M., Langebeek, N., Richter, C., Santegoets, R. M. W. J., Schrijnders-Gudde, L., van de Ven, B. J. M., Ormaasen, V., Aavitsland, P., Stanczak, J. J., Stanczak, G. P., Firlag-Burkacka, E., Wiercinska-Drapalo, A., Jablonowska, E., Malolepsza, E., Leszczyszyn-Pynka, M., Szata, W., Palma, C., Borges, F., Paix̃ao, T., Duque, V., Araújo, F., Jevtovic, D. J., Salemovic, D., Habekova, M., Mokráš, Miloš, Truska, P., Babic, Dunja Z., Tomazic, J., Vidmar, L., Karner, P., Gutíerrez, C., deMendoza, C., Erkicia, I., Domingo, P., Camino, X., Galindo, M. J., Blanco, J. L., Leal, M., Masabeu, A., Guelar, A., Llibre, J. M., Margall, N., Iribarren, J. A., Gutierrez, S., Baldov́i, J. F., Pedreira, J. D., Gatell, J. M., Moreno, S., de Mendoza, C., Soriano, V., Blaxhult, A., Heidarian, A., Karlsson, A., Aperia-Peipke, K., Bergbrant, I. -M, Gissĺen, M., Svennerholm, M., Björkman, Per, Bratt, G., Carlsson, M., Ekvall, H., Ericsson, M., Ḧofer, M., Johansson, B., Sonnerb̈org, A., Kuylenstierna, N., Ljungberg, B., Mäkitalo, S., Strand, A., Öberg, S., Virology, Erasmus MC other, Van Wijngaerden, Eric, Clinicum, Department of Medicine, Infektiosairauksien yksikkö, Centro de Malária e outras Doenças Tropicais (CMDT), Graduate School, Kostrikis, Leontios G. [0000-0002-5340-7109], Paraskevis, Dimitrios [0000-0001-6167-7152], UCL - SSS/IREC/MBLG - Pôle de Microbiologie médicale, UCL - (SLuc) Service de microbiologie, UCL - (SLuc) Service de médecine interne générale, Theys, K, Deforche, K, Vercauteren, J, Libin, P, van de Vijver, DA, Albert, J, Asjö, B, Balotta, C, Bruckova, M, Camacho, RJ, Clotet, B, Coughlan, S, Grossman, Z, Hamouda, O, Horban, A, Korn, K, Kostrikis, LG, Kücherer, C, Nielsen, C, Paraskevis, D, Poljak, M, Puchhammer Stockl, E, Riva, C, Ruiz, L, Liitsola, K, Schmit, JC, Schuurman, R, Sönnerborg, A, Stanekova, D, Stanojevic, M, Struck, D, Van Laethem, K, Wensing, AM, Boucher, CA, Vandamme, AM, Tramuto, F, and Vitale, F
- Subjects
Adult ,Male ,lcsh:Immunologic diseases. Allergy ,Anti-HIV Agents ,education ,Virulence ,HIV Infections ,Drug resistance ,Biology ,Settore MED/42 - Igiene Generale E Applicata ,Virus ,polymorphism ,03 medical and health sciences ,Viral Proteins ,SDG 3 - Good Health and Well-being ,Virology ,Genotype ,Drug Resistance, Viral ,drug-naive ,medicine ,Humans ,Prospective Studies ,030304 developmental biology ,0303 health sciences ,Polymorphism, Genetic ,030306 microbiology ,Research ,protease ,Viral Load ,Reverse transcriptase ,3. Good health ,CD4 Lymphocyte Count ,Drug-naïve ,Infectious Diseases ,3121 General medicine, internal medicine and other clinical medicine ,Immunology ,biology.protein ,HIV-1 ,Female ,Antibody ,lcsh:RC581-607 ,Viral load ,HIV-1 infected patient ,medicine.drug ,Peptide Hydrolases - Abstract
Background: The effect of drug resistance transmission on disease progression in the newly infected patient is not well understood. Major drug resistance mutations severely impair viral fitness in a drug free environment, and therefore expected to revert quickly. Compensatory mutations, often already polymorphic in wild-type viruses, do not tend to revert after transmission. While compensatory mutations increase fitness during treatment, their presence may also modulate viral fitness and virulence in absence of therapy and major resistance mutations. We previously designed a modeling technique that quantifies genotypic footprints of in vivo treatment selective pressure, including both drug resistance mutations and polymorphic compensatory mutations, through the quantitative description of a fitness landscape from virus genetic sequences. Results: Genotypic correlates of viral load and CD4 cell count were evaluated in subtype B sequences from recently diagnosed treatment-naive patients enrolled in the SPREAD programme. The association of surveillance drug resistance mutations, reported compensatory mutations and fitness estimated from drug selective pressure fitness landscapes with baseline viral load and CD4 cell count was evaluated using regression techniques. Protease genotypic variability estimated to increase fitness during treatment was associated with higher viral load and lower CD4 cell counts also in treatment-naive patients, which could primarily be attributed to well-known compensatory mutations at highly polymorphic positions. By contrast, treatment-related mutations in reverse transcriptase could not explain viral load or CD4 cell count variability. Conclusions: These results suggest that polymorphic compensatory mutations in protease, reported to be selected during treatment, may improve the replicative capacity of HIV-1 even in absence of drug selective pressure or major resistance mutations. The presence of this polymorphic variation may either reflect a history of drug selective pressure, i.e. transmission from a treated patient, or merely be a result of diversity in wild-type virus. Our findings suggest that transmitted drug resistance has the potential to contribute to faster disease progression in the newly infected host and to shape the HIV-1 epidemic at a population level. ispartof: Retrovirology vol:9 issue:1 ispartof: location:England status: published
- Published
- 2012
11. HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics
- Author
-
Abecasis, A.B. Wensing, A.M.J. Paraskevis, D. Vercauteren, J. Theys, K. Van de Vijver, D.A.M.C. Albert, J. Asjö, B. Balotta, C. Beshkov, D. Camacho, R.J. Clotet, B. De Gascun, C. Griskevicius, A. Grossman, Z. Hamouda, O. Horban, A. Kolupajeva, T. Korn, K. Kostrikis, L.G. Kücherer, C. Liitsola, K. Linka, M. Nielsen, C. Otelea, D. Paredes, R. Poljak, M. Puchhammer-Stöckl, E. Schmit, J.-C. Sönnerborg, A. Stanekova, D. Stanojevic, M. Struck, D. Boucher, C.A.B. Vandamme, A.-M.
- Abstract
Background: Understanding HIV-1 subtype distribution and epidemiology can assist preventive measures and clinical decisions. Sequence variation may affect antiviral drug resistance development, disease progression, evolutionary rates and transmission routes.Results: We investigated the subtype distribution of HIV-1 in Europe and Israel in a representative sample of patients diagnosed between 2002 and 2005 and related it to the demographic data available. 2793 PRO-RT sequences were subtyped either with the REGA Subtyping tool or by a manual procedure that included phylogenetic tree and recombination analysis. The most prevalent subtypes/CRFs in our dataset were subtype B (66.1%), followed by sub-subtype A1 (6.9%), subtype C (6.8%) and CRF02_AG (4.7%). Substantial differences in the proportion of new diagnoses with distinct subtypes were found between European countries: the lowest proportion of subtype B was found in Israel (27.9%) and Portugal (39.2%), while the highest was observed in Poland (96.2%) and Slovenia (93.6%). Other subtypes were significantly more diagnosed in immigrant populations. Subtype B was significantly more diagnosed in men than in women and in MSM > IDUs > heterosexuals. Furthermore, the subtype distribution according to continent of origin of the patients suggests they acquired their infection there or in Europe from compatriots.Conclusions: The association of subtype with demographic parameters suggests highly compartmentalized epidemics, determined by social and behavioural characteristics of the patients. © 2013 Abecasis et al.; licensee BioMed Central Ltd.
- Published
- 2013
12. The demise of multidrug-resistant HIV-1: the national time trend in Portugal
- Author
-
Vercauteren, J., Theys, K., Carvalho, A. P., Valadas, E., Duque, L. M., Teofilo, E., Faria, T., Faria, D., Vera, J., Aguas, M. J., Peres, S., Mansinho, K., Vandamme, A.-M., Camacho, R. J., Claudia Miranda, A., Aldir, I., Ventura, F., Nina, J., Borges, F., Doroana, M., Antunes, F., Joao Aleixo, M., Joao Aguas, M., Botas, J., Branco, T., Vaz Pinto, I., Pocas, J., Sa, J., Duque, L., Diniz, A., Mineiro, A., Gomes, F., Santos, C., Fonseca, P., Proenca, P., Tavares, L., Guerreiro, C., Narciso, J., Pinheiro, S., Germano, I., Caixas, U., Faria, N., Paula Reis, A., Bentes Jesus, M., Amaro, G., Roxo, F., Abreu, R., and Neves, I.
- Subjects
Microbiology (medical) ,Drug ,medicine.medical_specialty ,Anti-HIV Agents ,media_common.quotation_subject ,antiretroviral therapy ,Human immunodeficiency virus (HIV) ,Mutation, Missense ,HIV Infections ,Drug resistance ,medicine.disease_cause ,drug susceptibility ,resistance ,03 medical and health sciences ,Viral Proteins ,Acquired immunodeficiency syndrome (AIDS) ,Internal medicine ,Drug Resistance, Viral ,medicine ,Prevalence ,Humans ,Pharmacology (medical) ,030304 developmental biology ,media_common ,Original Research ,Pharmacology ,0303 health sciences ,CHLC MED ,Portugal ,030306 microbiology ,business.industry ,Drug susceptibility ,medicine.disease ,therapy failure ,Antiretroviral therapy ,Virology ,3. Good health ,Multiple drug resistance ,AIDS ,Infectious Diseases ,Cohort ,HIV-1 ,business - Abstract
Received 17 July 2012; returned 8 September 2012; revised 2 October 2012; accepted 30 October 2012Objectives: Despite a decreasing mortality and morbidity in treated HIV-1 patients, highly active antiretroviraltreatment (HAART) can still fail due to the development of drug resistance. Especially, multidrug-resistantviruses pose a threat to efficient therapy. We studied the changing prevalence of multidrug resistance (MDR)over time in a cohort of HIV-1-infected patients in Portugal.Patients and methods: We used data of 8065 HIV-1-infected patients followed from July 2001 up to April 2012in 22 hospitals located in Portugal. MDR at a specific date of sampling was defined as no more than one fullyactive drug (excluding integrase and entry inhibitors) at that time authorized by the Portuguese NationalAuthority of Medicines and Health Products (INFARMED), as interpreted with the Rega algorithm version8.0.2. A generalized linear mixed model was used to study the time trend of the prevalence of MDR.Results: We observed a statistically significant decrease in the prevalence of MDR over the last decade, from6.9% (95% CI: 5.7–8.4) in 2001–03, 6.0% (95% CI: 4.9–7.2) in 2003–05, 3.7% (95% CI: 2.8–4.8) in 2005–07and 1.6% (95% CI: 1.1–2.2) in 2007–09 down to 0.6% (95% CI: 0.3–0.9) in 2009–12 [OR¼0.80 (95% CI:0.75–0.86); P,0.001]. In July 2011 the last new case of MDR was seen.Conclusions: The prevalence of multidrug-resistant HIV-1 is decreasing over time in Portugal, reflecting the in-creasing efficiency of HAART and the availability of new drugs. Therefore, in designing a new drug, safety andpractical aspects, e.g. less toxicity and ease of use, may need more attention than focusing mainly on efficacyagainst resistant strains.Keywords: resistance, drug susceptibility, therapy failure, antiretroviral therapy, AIDS
- Published
- 2012
13. Characterization of amino acids Arg, Ser and Thr at position 70 within HIV-1 reverse transcriptase.
- Author
-
Megens, Sarah, De Wit, Stéphane, Bernatchez, J, Dekeersmaeker, Nathalie, Vinken, L, Covens, Kris, Theys, K, Camacho, Ricardo Jorge, Vandamme, Anne-Mieke, Gottesfeld, Joel M, Van Laethem, Kristel, Megens, Sarah, De Wit, Stéphane, Bernatchez, J, Dekeersmaeker, Nathalie, Vinken, L, Covens, Kris, Theys, K, Camacho, Ricardo Jorge, Vandamme, Anne-Mieke, Gottesfeld, Joel M, and Van Laethem, Kristel
- Abstract
The amino acid position 70 in HIV-1 reverse transcriptase (RT) plays an important role in nucleoside RT inhibitor (NRTI) resistance. K70R is part of the thymidine analog mutations, but also other amino acid changes have been associated with NRTI resistance, such as K70E and K70G. In this study, we investigated the in vivo selection of the HIV-1 RT mutations K70S and K70T and their in vitro effect on drug resistance and replication capacity., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2014
14. Characterization of amino acids Arg, Ser and Thr at position 70 within HIV-1 reverse transcriptase
- Author
-
Megens, S., primary, De Wit, S., additional, Bernatchez, J., additional, Dekeersmaeker, N., additional, Vinken, L., additional, Covens, K., additional, Theys, K., additional, Camacho, R. J., additional, Vandamme, A.-M., additional, Götte, M., additional, and Van Laethem, K., additional
- Published
- 2014
- Full Text
- View/download PDF
15. HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure
- Author
-
Sangeda, R.Z. (Raphael), Theys, K. (Kristof), Beheydt, G. (Gertjan), Rhee, S.Y. (Soo Yoon), Deforche, K. (Koen), Vercauteren, J. (Jurgen), Libin, P. (Pieter), Imbrechts, S. (Stijn), Grossman, Z. (Zehava), Camacho, R.J. (Ricardo Jorge), Laethem, K. (Kristel) van, Pironti, A. (Alejandro), Zazzi, M. (Maurizio), Sönnerborg, A. (Anders), Incardona, F. (Francesca), Luca, A. (Andrea) de, Torti, C. (Carlo), Ruiz, L. (Lidia), Vijver, D.A.M.C. (David) van de, Shafer, R.W. (Robert), Bruzzone, B. (Bianca), Wijngaerden, E. (Eric) van, Vandamme, A.M. (Anne Mieke), Sangeda, R.Z. (Raphael), Theys, K. (Kristof), Beheydt, G. (Gertjan), Rhee, S.Y. (Soo Yoon), Deforche, K. (Koen), Vercauteren, J. (Jurgen), Libin, P. (Pieter), Imbrechts, S. (Stijn), Grossman, Z. (Zehava), Camacho, R.J. (Ricardo Jorge), Laethem, K. (Kristel) van, Pironti, A. (Alejandro), Zazzi, M. (Maurizio), Sönnerborg, A. (Anders), Incardona, F. (Francesca), Luca, A. (Andrea) de, Torti, C. (Carlo), Ruiz, L. (Lidia), Vijver, D.A.M.C. (David) van de, Shafer, R.W. (Robert), Bruzzone, B. (Bianca), Wijngaerden, E. (Eric) van, and Vandamme, A.M. (Anne Mieke)
- Abstract
We previously modeled the in vivo evolution of human immunodeficiency virus-1 (HIV-1) under drug selective pressure from cross-sectional viral sequences. These fitness landscapes (FLs) were made by using first a Bayesian network (BN) to map epistatic substitutions, followed by scaling the fitness landscape based on an HIV evolution simulator trying to evolve the sequences from treatment naïve patients into sequences from patients failing treatment. In this study, we compared four FLs trained with different sequence populations. Epistatic interactions were learned from three different cross-sectional BNs, trained with sequence from patients experienced with indinavir (BNT), all protease inhibitors (PIs) (BNP) or all PI except indinavir (BND). Scaling the fitness landscape was done using cross-sectional data from drug naïve and indinavir experienced patients (Fcross using BNT) and using longitudinal sequences from patients failing indinavir (FlongT using BNT, FlongP using BNP, FlongD using BND). Evaluation to predict the failing sequence and therapy outcome was performed on independent sequences of patients on indinavir. Parameters included estimated fitness (LogF), the number of generations (GF) or mutations (MF) to reach the fitness threshold (average fitness when a major resistance mutation appeared), the number of generations (GR) or mutations (MR) to reach a major resistance mutation and compared to genotypic susceptibility score (GSS) from Rega and HIVdb algorithms. In pairwise FL comparisons we found significant correlation between fitness values for individual sequences, and this correlation improved after correcting for the subtype. Furthermore, FLs could predict the failing sequence under indinavir-containing combinations. At 12 and 48 weeks, all parameters from all FLs and indinavir GSS (both for Rega and HIVdb) were predictive of therapy outcome, except MR for FlongT and FlongP. The fitness landscapes have similar predictive power for treatment response un
- Published
- 2013
- Full Text
- View/download PDF
16. RegaDB: Community-driven data management and analysis for infectious diseases
- Author
-
Libin, P. (Pieter), Beheydt, G. (Gertjan), Deforche, K. (Koen), Imbrechts, S. (Stijn), Ferreira, F. (Fossie), Laethem, K. (Kristel) van, Theys, K. (Kristof), Carvalho, A.P. (Ana Patricia), Cavaco-Silva, J. (Joana), Lapadula, G. (Giuseppe), Torti, C. (Carlo), Assel, M. (Matthias), Wesner, S. (Stefan), Snoeck, M.M.J. (M. M J), Ruelle, J. (Jean), Bel, A.V. (Annelies) de, Lacor, P. (Patrick), Munter, P. (Paul) de, Wijngaerden, E. (Eric) van, Zazzi, M. (Maurizio), Kaiser, R. (Rolf), Ayouba, A. (Ahidjo), Peeters, M.C. (Marian), Oliveira, T. (Tulio) de, Alcantara, L.C.J. (Luiz), Grossman, Z. (Zehava), Sloot, P.M.A. (Peter), Otelea, D. (Dan), Paraschiv, C. (Corina), Boucher, C.A.B. (Charles), Camacho, R.J. (Ricardo Jorge), Vandamme, A.M. (Anne Mieke), Libin, P. (Pieter), Beheydt, G. (Gertjan), Deforche, K. (Koen), Imbrechts, S. (Stijn), Ferreira, F. (Fossie), Laethem, K. (Kristel) van, Theys, K. (Kristof), Carvalho, A.P. (Ana Patricia), Cavaco-Silva, J. (Joana), Lapadula, G. (Giuseppe), Torti, C. (Carlo), Assel, M. (Matthias), Wesner, S. (Stefan), Snoeck, M.M.J. (M. M J), Ruelle, J. (Jean), Bel, A.V. (Annelies) de, Lacor, P. (Patrick), Munter, P. (Paul) de, Wijngaerden, E. (Eric) van, Zazzi, M. (Maurizio), Kaiser, R. (Rolf), Ayouba, A. (Ahidjo), Peeters, M.C. (Marian), Oliveira, T. (Tulio) de, Alcantara, L.C.J. (Luiz), Grossman, Z. (Zehava), Sloot, P.M.A. (Peter), Otelea, D. (Dan), Paraschiv, C. (Corina), Boucher, C.A.B. (Charles), Camacho, R.J. (Ricardo Jorge), and Vandamme, A.M. (Anne Mieke)
- Abstract
Summary: RegaDB is a free and open source data management and analysis environment for infectious diseases. RegaDB allows clinicians to store, manage and analyse patient data, including viral genetic sequences. Moreover, RegaDB pro
- Published
- 2013
- Full Text
- View/download PDF
17. HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics
- Author
-
Abecasis, A.B. (Ana), Wensing, A.M.J. (Annemarie), Paraskevis, D. (Dimitrios), Vercauteren, J. (Jurgen), Theys, K. (Kristof), Vijver, D.A.M.C. (David) van de, Albert, J. (Jan), Åsjö, B. (Birgitta), Balotta, C. (Claudia), Beshkov, D. (Danail), Camacho, R.J. (Ricardo Jorge), Clotet, B., Gascun, C. (Cillian) de, Griskevicius, A. (Algirdas), Grossman, Z. (Zehava), Hamouda, O. (Osamah), Horban, A. (Andrzej), Kolupajeva, T. (Tatjana), Korn, K., Kostrikis, L.G. (Leondios), Kücherer, C. (Claudia), Liitsola, K. (Kirsi), Linka, M. (Marek), Nielsen, C. (Claus), Otelea, D. (Dan), Paredes, R. (Roger), Poljak, M. (Mario), Puchhammer-Stöckl, E. (Elisabeth), Schmit, J.-C. (Jean-Claude), Sonnerborg, A. (Anders), Stanekova, D. (Danica), Stanojevic, M. (Maja), Struck, D. (Daniel), Boucher, C.A.B. (Charles), Vandamme, A.M. (Anne Mieke), Abecasis, A.B. (Ana), Wensing, A.M.J. (Annemarie), Paraskevis, D. (Dimitrios), Vercauteren, J. (Jurgen), Theys, K. (Kristof), Vijver, D.A.M.C. (David) van de, Albert, J. (Jan), Åsjö, B. (Birgitta), Balotta, C. (Claudia), Beshkov, D. (Danail), Camacho, R.J. (Ricardo Jorge), Clotet, B., Gascun, C. (Cillian) de, Griskevicius, A. (Algirdas), Grossman, Z. (Zehava), Hamouda, O. (Osamah), Horban, A. (Andrzej), Kolupajeva, T. (Tatjana), Korn, K., Kostrikis, L.G. (Leondios), Kücherer, C. (Claudia), Liitsola, K. (Kirsi), Linka, M. (Marek), Nielsen, C. (Claus), Otelea, D. (Dan), Paredes, R. (Roger), Poljak, M. (Mario), Puchhammer-Stöckl, E. (Elisabeth), Schmit, J.-C. (Jean-Claude), Sonnerborg, A. (Anders), Stanekova, D. (Danica), Stanojevic, M. (Maja), Struck, D. (Daniel), Boucher, C.A.B. (Charles), and Vandamme, A.M. (Anne Mieke)
- Abstract
Background: Understanding HIV-1 subtype distribution and epidemiology can assist preventive measures and clinical decisions. Sequence variation may affect antiviral drug resistance development, disease progression, evolutionary rates and transmission routes.Results: We investigated the subtype distribution of HIV-1 in Europe and Israel in a representative sample of patients diagnosed between 2002 and 2005 and related it to the demographic data available. 2793 PRO-RT sequences were subtyped either with the REGA Subtyping tool or by a manual
- Published
- 2013
- Full Text
- View/download PDF
18. HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure
- Author
-
Sangeda, RZ, Theys, K, Beheydt, G, Rhee, SY, Deforche, K, Vercauteren, J, Libin, P, Imbrechts, S, Grossman, Z, Camacho, RJ, Van Laethem, K, Pironti, A, Zazzi, M, Sonnerborg, A, Incardona, F, Luca, A, Torti, C, Ruiz, L, van de Vijver, David, Shafer, RW, Bruzzone, B, van Wijngaerden, E, Vandamme, AM, Sangeda, RZ, Theys, K, Beheydt, G, Rhee, SY, Deforche, K, Vercauteren, J, Libin, P, Imbrechts, S, Grossman, Z, Camacho, RJ, Van Laethem, K, Pironti, A, Zazzi, M, Sonnerborg, A, Incardona, F, Luca, A, Torti, C, Ruiz, L, van de Vijver, David, Shafer, RW, Bruzzone, B, van Wijngaerden, E, and Vandamme, AM
- Abstract
We previously modeled the in vivo evolution of human immunodeficiency virus-1 (HIV-1) under drug selective pressure from cross-sectional viral sequences. These fitness landscapes (FLs) were made by using first a Bayesian network (BN) to map epistatic substitutions, followed by scaling the fitness landscape based on an HIV evolution simulator trying to evolve the sequences from treatment naive patients into sequences from patients failing treatment. In this study, we compared four FLs trained with different sequence populations. Epistatic interactions were learned from three different cross-sectional BNs, trained with sequence from patients experienced with indinavir (BNT), all protease inhibitors (PIs) (BNP) or all PI except indinavir (BND). Scaling the fitness landscape was done using cross-sectional data from drug naive and indinavir experienced patients (Fcross using BNT) and using longitudinal sequences from patients failing indinavir In pairwise FL comparisons we found significant correlation between fitness values for individual sequences, and this correlation improved after correcting for the subtype. Furthermore, FLs could predict the failing sequence under indinavir-containing combinations. At 12 and 48 weeks, all parameters from all FLs and indinavir GSS (both for Rega and HIVdb) were predictive of therapy outcome, except MR for FlongT and FlongP. The fitness landscapes have similar predictive power for treatment respon
- Published
- 2013
19. HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics
- Author
-
Abecasis, AB, Wensing, AMJ, Paraskevis, D, Vercauteren, J, Theys, K, van de Vijver, David, Albert, J, Asjo, B, Balotta, C, Beshkov, D, Camacho, RJ, Clotet, B, De Gascun, C, Griskevicius, A, Grossman, Z, Hamouda, O, Horban, A, Kolupajeva, T, Korn, K, Kostrikis, LG, Kucherer, C, Liitsola, K, Linka, M, Nielsen, C, Otelea, D, Paredes, R, Poljak, M, Puchhammer-Stockl, E, Schmit, JC, Sonnerborg, A, Stanekova, D, Stanojevic, M, Struck, D, Boucher, Charles, Vandamme, AM, Abecasis, AB, Wensing, AMJ, Paraskevis, D, Vercauteren, J, Theys, K, van de Vijver, David, Albert, J, Asjo, B, Balotta, C, Beshkov, D, Camacho, RJ, Clotet, B, De Gascun, C, Griskevicius, A, Grossman, Z, Hamouda, O, Horban, A, Kolupajeva, T, Korn, K, Kostrikis, LG, Kucherer, C, Liitsola, K, Linka, M, Nielsen, C, Otelea, D, Paredes, R, Poljak, M, Puchhammer-Stockl, E, Schmit, JC, Sonnerborg, A, Stanekova, D, Stanojevic, M, Struck, D, Boucher, Charles, and Vandamme, AM
- Abstract
Background: Understanding HIV-1 subtype distribution and epidemiology can assist preventive measures and clinical decisions. Sequence variation may affect antiviral drug resistance development, disease progression, evolutionary rates and transmission routes. Results: We investigated the subtype distribution of HIV-1 in Europe and Israel in a representative sample of patients diagnosed between 2002 and 2005 and related it to the demographic data available. 2793 PRO-RT sequences were subtyped either with the REGA Subtyping tool or by a manual procedure that included phylogenetic tree and recombination analysis. The most prevalent subtypes/CRFs in our dataset were subtype B (66.1%), followed by sub-subtype A1 (6.9%), subtype C (6.8%) and CRF02_AG (4.7% Conclusions: The association of subtype with demographic parameters suggests highly compartmentalized epidemics, determined by social and behavioural characteristics of the patients.
- Published
- 2013
20. HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir
- Author
-
Theys, K, Vercauteren, J, Snoeck, J, Zazzi, M, Camacho, Rj, Torti, C, Schülter, E, Clotet, B, Sönnerborg, A, De Luca, Andrea, Grossman, Z, Struck, D, Vandamme, A, Abecasis, Ab, De Luca, Andrea (ORCID:0000-0002-8311-6935), Theys, K, Vercauteren, J, Snoeck, J, Zazzi, M, Camacho, Rj, Torti, C, Schülter, E, Clotet, B, Sönnerborg, A, De Luca, Andrea, Grossman, Z, Struck, D, Vandamme, A, Abecasis, Ab, and De Luca, Andrea (ORCID:0000-0002-8311-6935)
- Abstract
Subtype-dependent selection of HIV-1 reverse transcriptase resistance mutation K65R was previously observed in cell culture and small clinical investigations. We compared K65R prevalence across subtypes A, B, C, F, G, and CRF02_AG separately in a cohort of 3,076 patients on combination therapy including tenofovir. K65R selection was significantly higher in HIV-1 subtype C. This could not be explained by clinical and demographic factors in multivariate analysis, suggesting subtype sequence-specific K65R pathways.
- Published
- 2013
21. Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients
- Author
-
Theys, K. (Kristof), Deforche, K. (Koen), Vercauteren, J. (Jurgen), Libin, P. (Pieter), Vijver, D.A.M.C. (David) van de, Albert, J. (Jan), Åsjö, B. (Birgitta), Balotta, C. (Claudia), Bruckova, M. (Marie), Camacho, R.J. (Ricardo Jorge), Clotet, B. (Bonaventura), Coughlan, S. (Suzie), Grossman, Z. (Zehava), Hamouda, O. (Osamah), Horban, A. (Andrzej), Korn, K. (Klaus), Kostrikis, L.G. (Leondios), Kücherer, C. (Claudia), Nielsen, C. (Claus), Paraskevis, D. (Dimitrios), Poljak, M. (Mario), Puchhammer-Stöckl, E. (Elisabeth), Riva, C. (Chiara), Ruiz, L. (Lidia), Liitsola, K. (Kirsi), Schmit, J.-C. (Jean-Claude), Schuurman, R. (Rob), Sonnerborg, A. (Anders), Stanekova, D. (Danica), Stanojevic, M. (Maja), Struck, D. (Daniel), Laethem, K. (Kristel) van, Wensing, A.M.J. (Annemarie), Boucher, C.A.B. (Charles), Vandamme, A.M. (Anne Mieke), Theys, K. (Kristof), Deforche, K. (Koen), Vercauteren, J. (Jurgen), Libin, P. (Pieter), Vijver, D.A.M.C. (David) van de, Albert, J. (Jan), Åsjö, B. (Birgitta), Balotta, C. (Claudia), Bruckova, M. (Marie), Camacho, R.J. (Ricardo Jorge), Clotet, B. (Bonaventura), Coughlan, S. (Suzie), Grossman, Z. (Zehava), Hamouda, O. (Osamah), Horban, A. (Andrzej), Korn, K. (Klaus), Kostrikis, L.G. (Leondios), Kücherer, C. (Claudia), Nielsen, C. (Claus), Paraskevis, D. (Dimitrios), Poljak, M. (Mario), Puchhammer-Stöckl, E. (Elisabeth), Riva, C. (Chiara), Ruiz, L. (Lidia), Liitsola, K. (Kirsi), Schmit, J.-C. (Jean-Claude), Schuurman, R. (Rob), Sonnerborg, A. (Anders), Stanekova, D. (Danica), Stanojevic, M. (Maja), Struck, D. (Daniel), Laethem, K. (Kristel) van, Wensing, A.M.J. (Annemarie), Boucher, C.A.B. (Charles), and Vandamme, A.M. (Anne Mieke)
- Abstract
Background: The effect of drug resistance transmission on disease progression in the newly infected patient is not well understood. Major drug resistance mutations severely impair viral fitness in a drug free environment, and therefore are expected to revert quickly. Compensatory mutations, often already polymorphic in wild-type viruses, do not tend to revert after transmission. While compensatory mutations increase
- Published
- 2012
- Full Text
- View/download PDF
22. Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients
- Author
-
Theys, K, Deforche, K, Vercauteren, J, Libin, P, van de Vijver, David, Albert, J (Jan), Asjo, B, Balotta, C, Bruckova, M, Camacho, RJ, Clotet, B, Coughlan, S, Grossman, Z, Hamouda, O, Horban, A, Korn, K, Kostrikis, LG, Kucherer, C, Nielsen, C, Paraskevis, D, Poljak, M, Puchhammer-Stockl, E, Riva, C, Ruiz, L, Liitsola, K, Schmit, JC, Schuurman, R (Rob), Sonnerborg, A, Stanekova, D, Stanojevic, M, Struck, D, Van Laethem, K, Wensing, AMJ, Boucher, Charles, Vandamme, AM, Theys, K, Deforche, K, Vercauteren, J, Libin, P, van de Vijver, David, Albert, J (Jan), Asjo, B, Balotta, C, Bruckova, M, Camacho, RJ, Clotet, B, Coughlan, S, Grossman, Z, Hamouda, O, Horban, A, Korn, K, Kostrikis, LG, Kucherer, C, Nielsen, C, Paraskevis, D, Poljak, M, Puchhammer-Stockl, E, Riva, C, Ruiz, L, Liitsola, K, Schmit, JC, Schuurman, R (Rob), Sonnerborg, A, Stanekova, D, Stanojevic, M, Struck, D, Van Laethem, K, Wensing, AMJ, Boucher, Charles, and Vandamme, AM
- Abstract
Background: The effect of drug resistance transmission on disease progression in the newly infected patient is not well understood. Major drug resistance mutations severely impair viral fitness in a drug free environment, and therefore are expected to revert quickly. Compensatory mutations, often already polymorphic in wild-type viruses, do not tend to revert after transmission. While compensatory mutations increase fitness during treatment, their presence may also modulate viral fitness and virulence in absence of therapy and major resistance mutations. We previously designed a modeling technique that quantifies genotypic footprints of in vivo treatment selective pressure, including both drug resistance mutations and polymorphic compensatory mutations, through the quantitative description of a fitness landscape from virus genetic sequences. Results: Genotypic correlates of viral load and CD4 cell count were evaluated in subtype B sequences from recently diagnosed treatment-naive patients enrolled in the SPREAD programme. The association of surveillance drug resistance mutations, reported compensatory mutations and fitness estimated from drug selective pressure fitness landscapes with baseline viral load and CD4 cell count was evaluated using regression techniques. Protease genotypic variability estimated to increase fitness during Conclusions: These results suggest that polymorphic compensatory mutations in protease, reported to be selected during treatment, may improve the replicative capacity of HIV-1 even in absence of drug selective pressure or major resistance mutations. The presence of this polymorphic variation may either reflect a history of drug selective pressure, i.e. transmission from a treated patient, or merely be a result of diversity in wild-type virus. Our findings suggest that transmitted drug resistance
- Published
- 2012
23. HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics
- Author
-
Abecasis, A. B., Wensing, A. M. J., Paraskevis, Dimitrios N., Vercauteren, J., Theys, K., Van de Vijver, D. A. M. C., Albert, Jan, Åsjö, Birgitta, Balotta, Claudia, Beshkov, Danail, Camacho, Ricardo J., Clotet, B., De Gascun, C., Griskevicius, A., Grossman, Z., Hamouda, O., Horban, A., Kolupajeva, T., Korn, K., Kostrikis, Leontios G., Kücherer, C., Liitsola, K., Linka, M., Nielsen, C., Otelea, D., Paredes, R., Poljak, M., Puchhammer-Stöckl, E., Schmit, J. -C, Sönnerborg, A., Stanekova, D., Stanojevic, M., Struck, D., Boucher, C. A. B., Vandamme, A. -M, Virology, and Paraskevis, Dimitrios [0000-0001-6167-7152]
- Subjects
Male ,demography ,Slovenia ,Human immunodeficiency virus (HIV) ,Human immunodeficiency virus 1 ,Distribution (economics) ,HIV Infections ,medicine.disease_cause ,molecular epidemiology ,epidemic ,Risk Factors ,computer program ,Epidemiology ,Israel ,cladistics ,genetic recombination ,0303 health sciences ,Phylogenetic tree ,Transmission (medicine) ,adult ,article ,homosexuality ,virus transmission ,Subtyping ,3. Good health ,Europe ,female ,Infectious Diseases ,virus typing ,Female ,lcsh:Immunologic diseases. Allergy ,medicine.medical_specialty ,sex difference ,intravenous drug abuse ,immigrant ,Newly diagnosed ,Biology ,03 medical and health sciences ,Risk-Taking ,male ,SDG 3 - Good Health and Well-being ,Virology ,medicine ,Humans ,human ,phylogenetic tree ,Social Behavior ,Epidemics ,030304 developmental biology ,Portugal ,030306 microbiology ,business.industry ,Research ,Disease progression ,heterosexuality ,Bayes Theorem ,Human immunodeficiency virus 1 infection ,major clinical study ,amino acid sequence ,Socioeconomic Factors ,HIV-1 ,Human medicine ,Poland ,lcsh:RC581-607 ,business ,Demography - Abstract
Background: Understanding HIV-1 subtype distribution and epidemiology can assist preventive measures and clinical decisions. Sequence variation may affect antiviral drug resistance development, disease progression, evolutionary rates and transmission routes.Results: We investigated the subtype distribution of HIV-1 in Europe and Israel in a representative sample of patients diagnosed between 2002 and 2005 and related it to the demographic data available. 2793 PRO-RT sequences were subtyped either with the REGA Subtyping tool or by a manual procedure that included phylogenetic tree and recombination analysis. The most prevalent subtypes/CRFs in our dataset were subtype B (66.1%), followed by sub-subtype A1 (6.9%), subtype C (6.8%) and CRF02_AG (4.7%). Substantial differences in the proportion of new diagnoses with distinct subtypes were found between European countries: the lowest proportion of subtype B was found in Israel (27.9%) and Portugal (39.2%), while the highest was observed in Poland (96.2%) and Slovenia (93.6%). Other subtypes were significantly more diagnosed in immigrant populations. Subtype B was significantly more diagnosed in men than in women and in MSM > IDUs > heterosexuals. Furthermore, the subtype distribution according to continent of origin of the patients suggests they acquired their infection there or in Europe from compatriots.Conclusions: The association of subtype with demographic parameters suggests highly compartmentalized epidemics, determined by social and behavioural characteristics of the patients. © 2013 Abecasis et al. licensee BioMed Central Ltd. 10 Tradenames: REGA Subtyping Cited By :55
- Published
- 2013
- Full Text
- View/download PDF
24. HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir
- Author
-
Theys, K., primary, Vercauteren, J., additional, Snoeck, J., additional, Zazzi, M., additional, Camacho, R. J., additional, Torti, C., additional, Schulter, E., additional, Clotet, B., additional, Sonnerborg, A., additional, De Luca, A., additional, Grossman, Z., additional, Struck, D., additional, Vandamme, A.- M., additional, and Abecasis, A. B., additional
- Published
- 2012
- Full Text
- View/download PDF
25. Resistance pathways of human immunodeficiency virus type 1 against the combination of zidovudine and lamivudine
- Author
-
Theys, K., primary, Deforche, K., additional, Libin, P., additional, Camacho, R. J., additional, Van Laethem, K., additional, and Vandamme, A.-M., additional
- Published
- 2010
- Full Text
- View/download PDF
26. A collaborative environment allowing clinical investigations on integrated biomedical databases.
- Author
-
Assel M, van de Vijver D, Libin P, Theys K, Harezlak D, O Nualláin B, Nowakowski P, Bubak M, Vandamme A, Imbrechts S, Sangeda R, Jiang T, Frentz D, and Sloot P
- Published
- 2009
27. Sub-epidemics explain localized high prevalence of reduced susceptibility to rilpivirine in treatment-naive HIV-1 infected patients: subtype- and geographic compartmentalization of baseline resistance mutations
- Author
-
Theys K, Van Laethem K, Perpetua Gomes, Baele G, Ac, Pineda-Peña, Am, Vandamme, Rj, Camacho, and Ab, Abecasis
28. A new ensemble coevolution system for detecting HIV-1 protein coevolution
- Author
-
Li G, Theys K, Verheyen J, Pineda-Peña A, Khouri R, Piampongsant S, Mónica Eusébio, Ramon J, and Vandamme A
29. Proof-of-principle evaluation of predictive performance for therapy outcome of baseline estimated fitness and genetic barrier towards resistance in a clinical cohort of HIV-1-treated patients
- Author
-
Deforche, K., Cozzi-Lepri, A., Theys, K., Clotet, B., Camacho, R., Kjaer, J., Laethem, K., Phillips, A. N., Moreau, Y., Jens Lundgren, and Vandamme, A-M
30. Interactively exploring the global Dengue phylogeny with PhyloGeoTool
- Author
-
Libin, P. J. K., Vanden Eynden, E., Incardona, F., Nowe, A., Bezenchek, A., Sonnerborg, A., Anne-Mieke Vandamme, Theys, K., Baele, G., and Hiv, Euco Study Grp
31. Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response
- Author
-
Deforche K, Cozzi-Lepri A, Theys K, Clotet B, Rj, Camacho, Kjaer J, Van Laethem K, Phillips A, Moreau Y, Jd, Lundgren, Anne-Mieke Vandamme, and EuroSIDA Study Group
32. Understanding the changing prevalence of K65R
- Author
-
Theys, K. and Anne-Mieke Vandamme
33. A collaborative environment allowing clinical investigations on integrated biomedical databases
- Author
-
Assel M, van de Vijver D, Libin P, Theys K, Harezlak D, O Nualláin B, Nowakowski P, Bubak M, Anne-Mieke Vandamme, Imbrechts S, Sangeda R, Jiang T, Frentz D, Sloot P, Computational Science Lab (IVI, FNWI), and System and Network Engineering (IVI, FNWI)
- Abstract
In order to perform clinical investigations on integrated biomedical data sets and to predict virological and epidemiological outcome, medical experts require an IT-based collaborative environment that provides them a user-friendly space for building and executing their complex studies and workflows on largely available and high-quality data repositories. In this paper, the authors introduce such a novel collaborative working environment a so-called virtual laboratory for clinicians and medical researchers, which allows users to interactively access and browse several biomedical research databases and re-use relevant data sets within own designed experiments. Firstly, technical details on the integration of relevant data resources into the virtual laboratory infrastructure and specifically developed user interfaces are briefly explained. The second part describes research possibilities for medical scientists including potential application fields and benefits as using the virtual laboratory functionalities for a particular exemplary study.
34. Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir
- Author
-
Theys, K., Snoeck, J., Vercauteren, J., Abecasis, A. B., Vandamme, A.-M, Camacho, R. J., Theys, K., Snoeck, J., Vercauteren, J., Abecasis, A. B., Vandamme, A.-M, and Camacho, R. J.
- Abstract
Objectives The use of tenofovir is highly associated with the emergence of mutation K65R, which confers broad resistance to nucleoside/nucleotide analogue reverse transcriptase inhibitors (NRTIs), especially when tenofovir is combined with other NRTIs also selecting for K65R. Although recent HIV-1 treatment guidelines discouraging these combinations resulted in reduced K65R selection with tenofovir, updated information on the impact of currently recommended regimens on the population selection rate of K65R is presently lacking. Methods In this study, we evaluated changes over time in the selection rate of resistance mutation K65R in a large population of 2736 HIV-1-infected patients failing combination antiretroviral treatment between 2002 and 2010. Results The K65R resistance mutation was detected in 144 patients, a prevalence of 5.3%. A large majority of observed K65R cases were explained by the use of tenofovir, reflecting its wide use in clinical practice. However, changing patterns over time in NRTIs accompanying tenofovir resulted in a persistent decreasing probability of K65R selection by tenofovir-based therapy. The currently recommended NRTI combination tenofovir/emtricitabine was associated with a low probability of K65R emergence. For any given dual NRTI combination including tenofovir, higher selection rates of K65R were consistently observed with a non-nucleoside reverse transcriptase inhibitor than with a protease inhibitor as the third agent. Discussion Our finding of a stable time trend of K65R despite elevated use of tenofovir illustrates increased potency of current HIV-1 therapy including tenofovir
35. RegaDB: community-driven data management and analysis for infectious diseases
- Author
-
Dan Otelea, Eric Van Wijngaerden, Paul De Munter, Martine Peeters, Anne-Mieke Vandamme, Pieter Libin, Joke Snoeck, Stijn Imbrechts, Zehava Grossman, Stefan Wesner, Koen Deforche, Annelies De Bel, Luiz Carlos Junior Alcantara, Jean Ruelle, Ahidjo Ayouba, Simona Paraschiv, Matthias Assel, Kristof Theys, Fossie Ferreira, Gertjan Beheydt, Rolf Kaiser, Carlo Torti, Patrick Lacor, Ricardo Jorge Camacho, Maurizio Zazzi, Joana Cavaco-Silva, Kristel Van Laethem, Tulio de Oliveira, Charles A. Boucher, Giuseppe Lapadula, Peter M. A. Sloot, Ana Patricia Carvalho, Computational Science Lab (IVI, FNWI), Centro de Malária e outras Doenças Tropicais (CMDT), Libin, P, Beheydt, G, Deforche, K, Imbrechts, S, Ferreira, F, Van Laethem, K, Theys, K, Carvalho, A, Cavaco-Silva, J, Lapadula, G, Torti, C, Assel, M, Wesner, S, Snoeck, J, Ruelle, J, De Bel, A, Lacor, P, De Munter, P, Van Wijngaerden, E, Zazzi, M, Kaiser, R, Ayouba, A, Peeters, M, De Oliveira, T, Alcantara, L, Grossman, Z, Sloot, P, Otelea, D, Paraschiv, S, Boucher, C, Camacho, R, Vandamme, A, School of Computer Engineering, Cell biology, and Virology
- Subjects
Statistics and Probability ,Source code ,Databases, Factual ,Database Management Systems ,Humans ,Software ,Virus Diseases ,Computer science ,Interface (Java) ,Data management ,media_common.quotation_subject ,Databases and Ontologies ,Biochemistry ,World Wide Web ,Databases ,03 medical and health sciences ,Documentation ,SDG 3 - Good Health and Well-being ,Database Management System ,Molecular Biology ,Factual ,030304 developmental biology ,media_common ,0303 health sciences ,030306 microbiology ,business.industry ,Engineering::Computer science and engineering::Computer applications::Life and medical sciences [DRNTU] ,Applications Notes ,Data science ,3. Good health ,Computer Science Applications ,Computational Mathematics ,Computational Theory and Mathematics ,business ,Human - Abstract
Summary: RegaDB is a free and open source data management and analysis environment for infectious diseases. RegaDB allows clinicians to store, manage and analyze patient data, including viral genetic sequences. Moreover, RegaDB provides researchers with a mechanism to collect data in a uniform format and offers them a canvas to make newly developed bioinformatics tools available to clinicians and virologists through a user friendly interface. Availability and implementation: Source code, binaries and documentation are available on http://regaweb.med.kuleuven.be/software/regadb/ RegaDB is written in the Java programming language, using a web-service oriented architecture. Contact: pieter.libin@rega.kuleuven.be Supplementary information: Supplementary material demonstrating the functionalities of the system is available at Bioinformatics online. Published version
- Published
- 2013
36. Analyses of Early ZIKV Genomes Are Consistent with Viral Spread from Northeast Brazil to the Americas.
- Author
-
de Moraes L, Portilho MM, Vrancken B, Van den Broeck F, Santos LA, Cucco M, Tauro LB, Kikuti M, Silva MMO, Campos GS, Reis MG, Barral A, Barral-Netto M, Boaventura VS, Vandamme AM, Theys K, Lemey P, Ribeiro GS, and Khouri R
- Subjects
- Humans, Brazil epidemiology, Phylogeny, Americas epidemiology, Zika Virus genetics, Zika Virus Infection
- Abstract
The Americas, particularly Brazil, were greatly impacted by the widespread Zika virus (ZIKV) outbreak in 2015 and 2016. Efforts were made to implement genomic surveillance of ZIKV as part of the public health responses. The accuracy of spatiotemporal reconstructions of the epidemic spread relies on the unbiased sampling of the transmission process. In the early stages of the outbreak, we recruited patients exhibiting clinical symptoms of arbovirus-like infection from Salvador and Campo Formoso, Bahia, in Northeast Brazil. Between May 2015 and June 2016, we identified 21 cases of acute ZIKV infection and subsequently recovered 14 near full-length sequences using the amplicon tiling multiplex approach with nanopore sequencing. We performed a time-calibrated discrete phylogeographic analysis to trace the spread and migration history of the ZIKV. Our phylogenetic analysis supports a consistent relationship between ZIKV migration from Northeast to Southeast Brazil and its subsequent dissemination beyond Brazil. Additionally, our analysis provides insights into the migration of ZIKV from Brazil to Haiti and the role Brazil played in the spread of ZIKV to other countries, such as Singapore, the USA, and the Dominican Republic. The data generated by this study enhances our understanding of ZIKV dynamics and supports the existing knowledge, which can aid in future surveillance efforts against the virus.
- Published
- 2023
- Full Text
- View/download PDF
37. Genome-wide diversity of Zika virus: Exploring spatio-temporal dynamics to guide a new nomenclature proposal.
- Author
-
Seabra SG, Libin PJK, Theys K, Zhukova A, Potter BI, Nebenzahl-Guimaraes H, Gorbalenya AE, Sidorov IA, Pimentel V, Pingarilho M, de Vasconcelos ATR, Dellicour S, Khouri R, Gascuel O, Vandamme AM, Baele G, Cuypers L, and Abecasis AB
- Abstract
The Zika virus (ZIKV) disease caused a public health emergency of international concern that started in February 2016. The overall number of ZIKV-related cases increased until November 2016, after which it declined sharply. While the evaluation of the potential risk and impact of future arbovirus epidemics remains challenging, intensified surveillance efforts along with a scale-up of ZIKV whole-genome sequencing provide an opportunity to understand the patterns of genetic diversity, evolution, and spread of ZIKV. However, a classification system that reflects the true extent of ZIKV genetic variation is lacking. Our objective was to characterize ZIKV genetic diversity and phylodynamics, identify genomic footprints of differentiation patterns, and propose a dynamic classification system that reflects its divergence levels. We analysed a curated dataset of 762 publicly available sequences spanning the full-length coding region of ZIKV from across its geographical span and collected between 1947 and 2021. The definition of genetic groups was based on comprehensive evolutionary dynamics analyses, which included recombination and phylogenetic analyses, within- and between-group pairwise genetic distances comparison, detection of selective pressure, and clustering analyses. Evidence for potential recombination events was detected in a few sequences. However, we argue that these events are likely due to sequencing errors as proposed in previous studies. There was evidence of strong purifying selection, widespread across the genome, as also detected for other arboviruses. A total of 50 sites showed evidence of positive selection, and for a few of these sites, there was amino acid (AA) differentiation between genetic clusters. Two main genetic clusters were defined, ZA and ZB, which correspond to the already characterized 'African' and 'Asian' genotypes, respectively. Within ZB, two subgroups, ZB.1 and ZB.2, represent the Asiatic and the American (and Oceania) lineages, respectively. ZB.1 is further subdivided into ZB.1.0 (a basal Malaysia sequence sampled in the 1960s and a recent Indian sequence), ZB.1.1 (South-Eastern Asia, Southern Asia, and Micronesia sequences), and ZB.1.2 (very similar sequences from the outbreak in Singapore). ZB.2 is subdivided into ZB.2.0 (basal American sequences and the sequences from French Polynesia, the putative origin of South America introduction), ZB.2.1 (Central America), and ZB.2.2 (Caribbean and North America). This classification system does not use geographical references and is flexible to accommodate potential future lineages. It will be a helpful tool for studies that involve analyses of ZIKV genomic variation and its association with pathogenicity and serve as a starting point for the public health surveillance and response to on-going and future epidemics and to outbreaks that lead to the emergence of new variants., (© The Author(s) 2022. Published by Oxford University Press.)
- Published
- 2022
- Full Text
- View/download PDF
38. Computational strategies to combat COVID-19: useful tools to accelerate SARS-CoV-2 and coronavirus research.
- Author
-
Hufsky F, Lamkiewicz K, Almeida A, Aouacheria A, Arighi C, Bateman A, Baumbach J, Beerenwinkel N, Brandt C, Cacciabue M, Chuguransky S, Drechsel O, Finn RD, Fritz A, Fuchs S, Hattab G, Hauschild AC, Heider D, Hoffmann M, Hölzer M, Hoops S, Kaderali L, Kalvari I, von Kleist M, Kmiecinski R, Kühnert D, Lasso G, Libin P, List M, Löchel HF, Martin MJ, Martin R, Matschinske J, McHardy AC, Mendes P, Mistry J, Navratil V, Nawrocki EP, O'Toole ÁN, Ontiveros-Palacios N, Petrov AI, Rangel-Pineros G, Redaschi N, Reimering S, Reinert K, Reyes A, Richardson L, Robertson DL, Sadegh S, Singer JB, Theys K, Upton C, Welzel M, Williams L, and Marz M
- Subjects
- Biomedical Research, COVID-19 epidemiology, COVID-19 virology, Genome, Viral, Humans, Pandemics, SARS-CoV-2 genetics, COVID-19 prevention & control, Computational Biology, SARS-CoV-2 isolation & purification
- Abstract
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is a novel virus of the family Coronaviridae. The virus causes the infectious disease COVID-19. The biology of coronaviruses has been studied for many years. However, bioinformatics tools designed explicitly for SARS-CoV-2 have only recently been developed as a rapid reaction to the need for fast detection, understanding and treatment of COVID-19. To control the ongoing COVID-19 pandemic, it is of utmost importance to get insight into the evolution and pathogenesis of the virus. In this review, we cover bioinformatics workflows and tools for the routine detection of SARS-CoV-2 infection, the reliable analysis of sequencing data, the tracking of the COVID-19 pandemic and evaluation of containment measures, the study of coronavirus evolution, the discovery of potential drug targets and development of therapeutic strategies. For each tool, we briefly describe its use case and how it advances research specifically for SARS-CoV-2. All tools are free to use and available online, either through web applications or public code repositories. Contact:evbc@unj-jena.de., (© The Author(s) 2020. Published by Oxford University Press.)
- Published
- 2021
- Full Text
- View/download PDF
39. Increasing Prevalence of HIV-1 Transmitted Drug Resistance in Portugal: Implications for First Line Treatment Recommendations.
- Author
-
Pingarilho M, Pimentel V, Diogo I, Fernandes S, Miranda M, Pineda-Pena A, Libin P, Theys K, Martins MRO, Vandamme AM, Camacho R, Gomes P, and Abecasis A
- Subjects
- Adolescent, Adult, Anti-HIV Agents pharmacology, Female, Genotype, HIV Infections drug therapy, HIV-1 genetics, Humans, Male, Middle Aged, Mutation, Phylogeny, Portugal epidemiology, Prevalence, Public Health methods, Reverse Transcriptase Inhibitors pharmacology, Reverse Transcriptase Inhibitors therapeutic use, Young Adult, Anti-HIV Agents therapeutic use, Drug Resistance, Viral, HIV Infections epidemiology, HIV Infections transmission, HIV-1 drug effects
- Abstract
Introduction: Treatment for All recommendations have allowed access to antiretroviral (ARV) treatment for an increasing number of patients. This minimizes the transmission of infection but can potentiate the risk of transmitted (TDR) and acquired drug resistance (ADR)., Objective: To study the trends of TDR and ADR in patients followed up in Portuguese hospitals between 2001 and 2017., Methods: In total, 11,911 patients of the Portuguese REGA database were included. TDR was defined as the presence of one or more surveillance drug resistance mutation according to the WHO surveillance list. Genotypic resistance to ARV was evaluated with Stanford HIVdb v7.0. Patterns of TDR, ADR and the prevalence of mutations over time were analyzed using logistic regression., Results and Discussion: The prevalence of TDR increased from 7.9% in 2003 to 13.1% in 2017 ( p < 0.001). This was due to a significant increase in both resistance to nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleotide reverse transcriptase inhibitors (NNRTIs), from 5.6% to 6.7% ( p = 0.002) and 2.9% to 8.9% ( p < 0.001), respectively. TDR was associated with infection with subtype B, and with lower viral load levels ( p < 0.05). The prevalence of ADR declined from 86.6% in 2001 to 51.0% in 2017 ( p < 0.001), caused by decreasing drug resistance to all antiretroviral (ARV) classes ( p < 0.001)., Conclusions: While ADR has been decreasing since 2001, TDR has been increasing, reaching a value of 13.1% by the end of 2017. It is urgently necessary to develop public health programs to monitor the levels and patterns of TDR in newly diagnosed patients., Competing Interests: The authors declare that they have no conflict of interests.
- Published
- 2020
- Full Text
- View/download PDF
40. Drivers of HIV-1 transmission: The Portuguese case.
- Author
-
Pineda-Peña AC, Pingarilho M, Li G, Vrancken B, Libin P, Gomes P, Camacho RJ, Theys K, and Barroso Abecasis A
- Subjects
- Age Factors, Antiretroviral Therapy, Highly Active, Drug Resistance, Viral, Female, Follow-Up Studies, Genotype, HIV Infections drug therapy, HIV Infections virology, Humans, Male, Odds Ratio, Portugal epidemiology, Prevalence, Public Health Surveillance, Sex Factors, Socioeconomic Factors, Young Adult, HIV Infections epidemiology, HIV Infections transmission, HIV-1 drug effects, HIV-1 genetics
- Abstract
Background: Portugal has one of the most severe HIV-1 epidemics in Western Europe. Two subtypes circulate in parallel since the beginning of the epidemic. Comparing their transmission patterns and its association with transmitted drug resistance (TDR) is important to pinpoint transmission hotspots and to develop evidence-based treatment guidelines., Methods: Demographic, clinical and genomic data were collected from 3599 HIV-1 naive patients between 2001 and 2014. Sequences obtained from drug resistance testing were used for subtyping, TDR determination and transmission clusters (TC) analyses., Results: In Portugal, transmission of subtype B was significantly associated with young males, while transmission of subtype G was associated with older heterosexuals. In Portuguese originated people, there was a decreasing trend both for prevalence of subtype G and for number of TCs in this subtype. The active TCs that were identified (i.e. clusters originated after 2008) were associated with subtype B-infected males residing in Lisbon. TDR was significantly different when comparing subtypes B (10.8% [9.5-12.2]) and G (7.6% [6.4-9.0]) (p = 0.001)., Discussion: TC analyses shows that, in Portugal, the subtype B epidemic is active and fueled by young male patients residing in Lisbon, while transmission of subtype G is decreasing. Despite similar treatment rates for both subtypes in Portugal, TDR is significantly different between subtypes., Competing Interests: ABA received funding from two commercial sources: LÓreal Portugal, through the research award L'Oréal Portugal Medals of Honor for Women in Science (2012) and Gilead Génese HIVLatePresenters. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
- Published
- 2019
- Full Text
- View/download PDF
41. Advances in Visualization Tools for Phylogenomic and Phylodynamic Studies of Viral Diseases.
- Author
-
Theys K, Lemey P, Vandamme AM, and Baele G
- Abstract
Genomic and epidemiological monitoring have become an integral part of our response to emerging and ongoing epidemics of viral infectious diseases. Advances in high-throughput sequencing, including portable genomic sequencing at reduced costs and turnaround time, are paralleled by continuing developments in methodology to infer evolutionary histories (dynamics/patterns) and to identify factors driving viral spread in space and time. The traditionally static nature of visualizing phylogenetic trees that represent these evolutionary relationships/processes has also evolved, albeit perhaps at a slower rate. Advanced visualization tools with increased resolution assist in drawing conclusions from phylogenetic estimates and may even have potential to better inform public health and treatment decisions, but the design (and choice of what analyses are shown) is hindered by the complexity of information embedded within current phylogenetic models and the integration of available meta-data. In this review, we discuss visualization challenges for the interpretation and exploration of reconstructed histories of viral epidemics that arose from increasing volumes of sequence data and the wealth of additional data layers that can be integrated. We focus on solutions that address joint temporal and spatial visualization but also consider what the future may bring in terms of visualization and how this may become of value for the coming era of real-time digital pathogen surveillance, where actionable results and adequate intervention strategies need to be obtained within days.
- Published
- 2019
- Full Text
- View/download PDF
42. An Evolutionary Model-Based Approach To Quantify the Genetic Barrier to Drug Resistance in Fast-Evolving Viruses and Its Application to HIV-1 Subtypes and Integrase Inhibitors.
- Author
-
Theys K, Libin PJK, Van Laethem K, and Abecasis AB
- Subjects
- Genotype, HIV Infections virology, HIV Reverse Transcriptase metabolism, Humans, Mutation drug effects, Mutation genetics, Polymorphism, Genetic drug effects, Polymorphism, Genetic genetics, Drug Resistance, Viral drug effects, Drug Resistance, Viral genetics, HIV Infections drug therapy, HIV Integrase Inhibitors pharmacology, HIV-1 drug effects, HIV-1 genetics, Integrases metabolism
- Abstract
Viral pathogens causing global disease burdens are often characterized by high rates of evolutionary changes. The extensive viral diversity at baseline can shorten the time to escape from therapeutic or immune selective pressure and alter mutational pathways. The impact of genotypic background on the barrier to resistance can be difficult to capture, particularly for agents in experimental stages or that are recently approved or expanded into new patient populations. We developed an evolutionary model-based counting method to quickly quantify the population genetic potential to resistance and assess population differences. We demonstrate its applicability to HIV-1 integrase inhibitors, as their increasing use globally contrasts with limited availability of non-B subtype resistant sequence data and corresponding knowledge gap. A large sequence data set encompassing most prevailing HIV-1 subtypes and resistance-associated mutations of currently approved integrase inhibitors was investigated. A complex interplay between codon predominance, polymorphisms, and associated evolutionary costs resulted in a subtype-dependent varied genetic potential for 15 resistance mutations against integrase inhibitors. While we confirm the lower genetic barrier of subtype B for G140S, we convincingly discard a similar effect previously suggested for G140C. A supplementary analysis for HIV-1 reverse transcriptase inhibitors identified a lower genetic barrier for K65R in subtype C through differential codon usage not reported before. To aid evolutionary interpretations of genomic differences for antiviral strategies, we advanced existing counting methods with increased sensitivity to identify subtype dependencies of resistance emergence. Future applications include novel HIV-1 drug classes or vaccines, as well as other viral pathogens., (Copyright © 2019 American Society for Microbiology.)
- Published
- 2019
- Full Text
- View/download PDF
43. VIRULIGN: fast codon-correct alignment and annotation of viral genomes.
- Author
-
Libin PJK, Deforche K, Abecasis AB, and Theys K
- Subjects
- Codon, Genome, Viral, Software
- Abstract
Summary: Virus sequence data are an essential resource for reconstructing spatiotemporal dynamics of viral spread as well as to inform treatment and prevention strategies. However, the potential benefit of these applications critically depends on accurate and correctly annotated alignments of genetically heterogeneous data. VIRULIGN was built for fast codon-correct alignments of large datasets, with standardized and formalized genome annotation and various alignment export formats., Availability and Implementation: VIRULIGN is freely available at https://github.com/rega-cev/virulign as an open source software project., Supplementary Information: Supplementary data is available at Bioinformatics online., (© The Author(s) 2018. Published by Oxford University Press.)
- Published
- 2019
- Full Text
- View/download PDF
44. A computational method for the identification of Dengue, Zika and Chikungunya virus species and genotypes.
- Author
-
Fonseca V, Libin PJK, Theys K, Faria NR, Nunes MRT, Restovic MI, Freire M, Giovanetti M, Cuypers L, Nowé A, Abecasis A, Deforche K, Santiago GA, Siqueira IC, San EJ, Machado KCB, Azevedo V, Filippis AMB, Cunha RVD, Pybus OG, Vandamme AM, Alcantara LCJ, and de Oliveira T
- Subjects
- Chikungunya Fever virology, Chikungunya virus classification, Chikungunya virus genetics, Dengue virology, Dengue Virus classification, Dengue Virus genetics, Genome, Viral, Genotype, Phylogeny, Zika Virus classification, Zika Virus genetics, Zika Virus Infection virology, Chikungunya virus isolation & purification, Computational Biology methods, Dengue Virus isolation & purification, Zika Virus isolation & purification
- Abstract
In recent years, an increasing number of outbreaks of Dengue, Chikungunya and Zika viruses have been reported in Asia and the Americas. Monitoring virus genotype diversity is crucial to understand the emergence and spread of outbreaks, both aspects that are vital to develop effective prevention and treatment strategies. Hence, we developed an efficient method to classify virus sequences with respect to their species and sub-species (i.e. serotype and/or genotype). This tool provides an easy-to-use software implementation of this new method and was validated on a large dataset assessing the classification performance with respect to whole-genome sequences and partial-genome sequences. Available online: http://krisp.org.za/tools.php., Competing Interests: Dr. Koen Deforche is one of the owners of the commercial company, EMWEB.
- Published
- 2019
- Full Text
- View/download PDF
45. SANTA-SIM: simulating viral sequence evolution dynamics under selection and recombination.
- Author
-
Jariani A, Warth C, Deforche K, Libin P, Drummond AJ, Rambaut A, Matsen Iv FA, and Theys K
- Abstract
Simulations are widely used to provide expectations and predictive distributions under known conditions against which to compare empirical data. Such simulations are also invaluable for testing and comparing the behaviour and power of inference methods. We describe SANTA-SIM, a software package to simulate the evolution of a population of gene sequences forwards through time. It models the underlying biological processes as discrete components: replication, recombination, point mutations, insertion-deletions, and selection under various fitness models and population size dynamics. The software is designed to be intuitive to work with for a wide range of users and executable in a cross-platform manner.
- Published
- 2019
- Full Text
- View/download PDF
46. Correction: Within-patient mutation frequencies reveal fitness costs of CpG dinucleotides and drastic amino acid changes in HIV.
- Author
-
Theys K, Feder AF, Gelbart M, Hartl M, Stern A, and Pennings PS
- Abstract
[This corrects the article DOI: 10.1371/journal.pgen.1007420.].
- Published
- 2018
- Full Text
- View/download PDF
47. Time to Harmonize Dengue Nomenclature and Classification.
- Author
-
Cuypers L, Libin PJK, Simmonds P, Nowé A, Muñoz-Jordán J, Alcantara LCJ, Vandamme AM, Santiago GA, and Theys K
- Subjects
- Dengue Virus genetics, Genetic Variation, Genotype, Humans, Phylogeny, Terminology as Topic, Dengue virology, Dengue Virus classification, Dengue Virus isolation & purification
- Abstract
Dengue virus (DENV) is estimated to cause 390 million infections per year worldwide. A quarter of these infections manifest clinically and are associated with a morbidity and mortality that put a significant burden on the affected regions. Reports of increased frequency, intensity, and extended geographical range of outbreaks highlight the virus's ongoing global spread. Persistent transmission in endemic areas and the emergence in territories formerly devoid of transmission have shaped DENV's current genetic diversity and divergence. This genetic layout is hierarchically organized in serotypes, genotypes, and sub-genotypic clades. While serotypes are well defined, the genotype nomenclature and classification system lack consistency, which complicates a broader analysis of their clinical and epidemiological characteristics. We identify five key challenges: (1) Currently, there is no formal definition of a DENV genotype; (2) Two different nomenclature systems are used in parallel, which causes significant confusion; (3) A standardized classification procedure is lacking so far; (4) No formal definition of sub-genotypic clades is in place; (5) There is no consensus on how to report antigenic diversity. Therefore, we believe that the time is right to re-evaluate DENV genetic diversity in an essential effort to provide harmonization across DENV studies.
- Published
- 2018
- Full Text
- View/download PDF
48. Within-patient mutation frequencies reveal fitness costs of CpG dinucleotides and drastic amino acid changes in HIV.
- Author
-
Theys K, Feder AF, Gelbart M, Hartl M, Stern A, and Pennings PS
- Subjects
- Amino Acids, Databases, Genetic, Female, Gene Products, pol genetics, HIV genetics, HIV Infections genetics, Humans, Male, Mutation, Sequence Analysis, DNA methods, Sequence Analysis, Protein, Silent Mutation genetics, Virus Replication, Genes, pol genetics, HIV-1 genetics, Mutation Rate
- Abstract
HIV has a high mutation rate, which contributes to its ability to evolve quickly. However, we know little about the fitness costs of individual HIV mutations in vivo, their distribution and the different factors shaping the viral fitness landscape. We calculated the mean frequency of transition mutations at 870 sites of the pol gene in 160 patients, allowing us to determine the cost of these mutations. As expected, we found high costs for non-synonymous and nonsense mutations as compared to synonymous mutations. In addition, we found that non-synonymous mutations that lead to drastic amino acid changes are twice as costly as those that do not and mutations that create new CpG dinucleotides are also twice as costly as those that do not. We also found that G→A and C→T mutations are more costly than A→G mutations. We anticipate that our new in vivo frequency-based approach will provide insights into the fitness landscape and evolvability of not only HIV, but a variety of microbes., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2018
- Full Text
- View/download PDF
49. A genetic IFN/STAT1/FAS axis determines CD4 T stem cell memory levels and apoptosis in healthy controls and Adult T-cell Leukemia patients.
- Author
-
Khouri R, Silva-Santos G, Dierckx T, Menezes SM, Decanine D, Theys K, Silva AC, Farré L, Bittencourt A, Mangino M, Roederer M, Vandamme AM, and Van Weyenbergh J
- Abstract
Adult T-cell leukemia (ATL) is an aggressive, chemotherapy-resistant CD4
+ CD25+ leukemia caused by HTLV-1 infection, which usually develops in a minority of patients several decades after infection. IFN + AZT combination therapy has shown clinical benefit in ATL, although its mechanism of action remains unclear. We have previously shown that an IFN-responsive FAS promoter polymorphism in a STAT1 binding site (rs1800682) is associated to ATL susceptibility and survival. Recently, CD4 T stem cell memory (TSCM ) Fashi cells have been identified as the hierarchical cellular apex of ATL, but a possible link between FAS, apoptosis, proliferation and IFN response in ATL has not been studied. In this study, we found significant ex vivo antiproliferative, antiviral and immunomodulatory effects of IFN-α treatment in short-term culture of primary mononuclear cells from ATL patients (n = 25). Bayesian Network analysis allowed us to integrate ex vivo IFN-α response with clinical, genetic and immunological data from ATL patients, thereby revealing a central role for FAS -670 polymorphism and apoptosis in the coordinated mechanism of action of IFN-α. FAS genotype-dependence of IFN-induced apoptosis was experimentally validated in an independent cohort of healthy controls (n = 20). The same FAS -670 polymorphism also determined CD4 TSCM levels in a genome-wide twin study (p = 7 × 10-11 , n = 460), confirming a genetic link between apoptosis and TSCM levels. Transcriptomic analysis and cell type deconvolution confirmed the FAS genotype/TSCM link and IFN-α-induced downregulation of CD4 TSCM -specific genes in ATL patient cells. In conclusion, ex vivo IFN-α treatment exerts a pleiotropic effect on primary ATL cells, with a genetic IFN/STAT1/Fas axis determining apoptosis vs. proliferation and underscoring the CD4 TSCM model of ATL leukemogenesis.- Published
- 2018
- Full Text
- View/download PDF
50. The impact of HIV-1 within-host evolution on transmission dynamics.
- Author
-
Theys K, Libin P, Pineda-Peña AC, Nowé A, Vandamme AM, and Abecasis AB
- Subjects
- Epidemics, HIV-1 pathogenicity, Host-Pathogen Interactions, Humans, Models, Theoretical, Virulence, Evolution, Molecular, HIV Infections transmission, HIV-1 genetics
- Abstract
The adaptive potential of HIV-1 is a vital mechanism to evade host immune responses and antiviral treatment. However, high evolutionary rates during persistent infection can impair transmission efficiency and alter disease progression in the new host, resulting in a delicate trade-off between within-host virulence and between-host infectiousness. This trade-off is visible in the disparity in evolutionary rates at within-host and between-host levels, and preferential transmission of ancestral donor viruses. Understanding the impact of within-host evolution for epidemiological studies is essential for the design of preventive and therapeutic measures. Herein, we review recent theoretical and experimental work that generated new insights into the complex link between within-host evolution and between-host fitness, revealing temporal and selective processes underlying the structure and dynamics of HIV-1 transmission., (Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.